Stockwinners Market Radar for February 23, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EST Gatos Silver sees FY23 silver production at 7.4M-8.2M oz - The company also states: "Silver equivalent production is expected to be between 12.4 and 13.8 million ounces, at an AISC on a co-product basis of between $15.50 and $17.50 per payable ounce. Sustaining capital expenditures are estimated at $45 million, significantly lower than 2022." CEO Dale Andres says: "The 2023 production and AISC guidance is consistent with the life of mine plan disclosed in October 2022. It reflects strong and consistent operational performance for the past 18 months, and our continued confidence in the quality of the CLG asset. With the recently completed paste backfill plant, CLG is well positioned to continue debottlenecking and business improvement efforts while continuing to control costs and maximize cash flows. Our objectives for the year include further optimizing operational performance, advancing mine life extension opportunities, accelerating definition drilling on the mineralization recently discovered at depth in the new South-East Deeps zone, and continuing exploration of the extensive land package in the highly prospective Los Gatos district. We continue to be a low-cost producer with substantial cash generation potential, and the Company expects to have the financial resources to fund planned exploration and future development expenses without new dilutive equity financings."

20:10 EST Cathie Wood's ARK Investment bought 458.4K shares of Unity today

18:55 EST Nektar down 31% afterhours after update on rezpegaldesleukin in lupus - Shares of Nektar Therapeutics are down 31.4% at $2.03 per share afterhours after the company provided Phase 2 data on rezpegaldesleukin in lupus. The company had stated that while the mid-dose level demonstrated a numeric improvement in SLEDAI-2K score as compared to placebo, the primary endpoint was not met.

18:45 EST JPMorgan CEO: It's possible interest rates could hit 6% - The Fed has to figure out what's the right thing in the long run. Jamie Dimon is speaking on CNBC.

18:32 EST Hudbay Minerals sees FY23 copper production up 10% - The company states that in FY23, its "consolidated copper production is forecast to increase by 10%ii to 114,000ii tonnes in 2023, compared to 2022, with higher grades from the Pampacancha deposit in Peru. Consolidated gold production is forecast to increase by 30%ii to 285,500ii ounces, compared to 2022, due to significantly higher gold production in Peru and Manitoba. Consolidated copper and gold production is expected to further increase in 2024, similar to the previously issued guidance, and 2025 copper and gold production is expected to benefit from an extension of mining activities at Pampacancha into the first half of 2025. Approximately $65 million reduction in growth capital expenditures and exploration spending is expected in 2023 compared to 2022. Total capital expenditures are expected to decline by 13% year-over-year to $300 million in 2023. Exploration expenditures are expected to decline by 61% in 2023 as activities are focused on areas with high potential for new discovery and mineral reserve and resource expansion."

18:27 EST Norfolk Southern says it is frustrated about East Palestine 'misinformation' - Norfolk Southern Corporation issued a statement in response to the National Transportation Safety Board's preliminary report on the East Palestine, Ohio train derailment: "Since the incident, Norfolk Southern has focused on supporting the Village of East Palestine and the NTSB throughout their investigation. NTSB investigators have worked tirelessly, and we appreciate everything they are doing. We share the NTSB Chair's frustration about the significant misinformation about the incident. Norfolk Southern will continue to support the NTSB's investigation. Their preliminary report indicates: The rail crew operated the train within the company's rules. The rail crew operated the train below the track speed limit. The wayside heat detectors were operating as designed. Once the rail crew was alerted by the wayside detector, they immediately began to stop the train. The company's wayside detectors on its network trigger an alarm at a temperature threshold that is among the lowest in the rail industry. At Norfolk Southern, our highest priority is the safety of our people and the communities and customers we serve. Under the supervision of the Federal Railroad Administration, the company has inspected all wayside detectors in the area of the incident and found they were operating as designed. Out of an abundance of caution, Norfolk Southern is now inspecting all of the nearly 1,000 wayside heat detectors on its system - on top of the regular inspection of the detectors every 30 days. We and the rail industry need to learn as much as we can from this event. Norfolk Southern will develop practices and invest in technologies that could help prevent an incident like this in the future. We will also work with the owners of the rail cars on the integrity and safety of the equipment we use. The speculation and misinformation about this incident have been extremely upsetting to the citizens of East Palestine. Norfolk Southern remains committed to the people of the community and will continue its work to help them thrive. Already, we have made significant progress in cleaning the site, engaging the community, and providing financial support for families and small businesses, all to help East Palestine."

18:00 EST Albemarle raises quarterly dividend to 40c per share - The dividend, which has an annualized rate of $1.60, is payable April 3 to shareholders of record at the close of business as of March 17. This year marks Albemarle's 29th consecutive year raising its dividend.

17:53 EST Enphase Energy exec sells $1.52M in common stock - In a regulatory filing, Enphase Energy disclosed that its Chief Commercial Officer David Ranhoff sold 7.5K shares of common stock on February 21st in a total transaction size of $1.52M.

17:46 EST Lockheed Martin awarded $170M Navy contract - Lockheed Martin was awarded a not-to-exceed $170M undefinitized cost-plus-fixed-fee order against a previously issued basic ordering agreement. This order provides non-recurring engineering for flight test instrumentation modifications to four production aircraft in support of the Joint Strike Fighter Program's Tech Refresh 3 and Block 4 weapons testing objectives and ship suitability testing for the Air Force, Marine Corps, Navy, and non-U.S. Department of Defense, or DOD, program participants. Work is expected to be completed in July 2026. FY23 research, development, test and evaluation funds in the amount of $6.86M; FY23 research, development, test and evaluation funds in the amount of $6,864,218; and non-U.S. DOD participant funds in the amount of $3,024,056 will be obligated at the time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:44 EST Cingulate announces top-line results from CTx-1301-003 study - Cingulate announced top-line results from the CTx-1301-003 study assessing the effect of food on absorption of its lead candidate CTx-1301. CTx-1301 is a novel, investigational, trimodal, extended-release tablet formulation of dexmethylphenidate, a compound approved by the FDA for the treatment of attention deficit/hyperactivity disorder, or ADHD. The trial demonstrated that CTx-1301 can be taken with or without food. Multiple pharmacokinetic, or PK, measurements were taken and adverse events were consistent with previous findings and indicate a favorable tolerability profile. In CTx-1301-003, 23 healthy adult subjects were randomized into one of two sequences to receive a single 25 mg dose of CTx-1301 on two occasions. Both doses were administered with 8 ounces of water and frequent blood samples were obtained for a period of 28 hours after each dose in order to define the absorption and elimination profile of dexmethyphenidate. The primary PK endpoints of this study were the maximum plasma concentration achieved after each dose as well as the extent of dexmethylphenidate absorbed into the blood expressed as the area the plasma drug concentration vs. time curve, or AUC. Knowledge of these two PK parameters which definine maximum and total extent of exposure are essential for a drug's regulatory approval. Full results, including data on secondary endpoints measuring half-life and time to onset, are being submitted for presentation at a forthcoming medical meeting.

17:41 EST Kratos Defense receives $49.57M Navy FRP contract - Kratos Defense announced that Kratos has received a $49.57M Full Rate Production, or FRP, contract for Lot 4 of the BQM-177A Subsonic Aerial Target, or SSAT, from the U.S. Navy for the procurement of an additional 55 aircraft, mission kits, certain flight consumables, and technical data.

17:37 EST Verra Mobility to replace Columbia Banking in S&P 600 at open on 3/1 - S&P SmallCap 600 constituent Columbia Banking System (COLB) will replace Umpqua Holdings Corp. (UMPQ) in the S&P MidCap 400, and Verra Mobility Corp. (VRRM) will replace Columbia Banking System in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 1. Columbia Banking System is acquiring Umpqua Holdings in a deal expected to be completed soon, pending final closing conditions. Post-merger, Columbia Banking System will have a market capitalization more representative of the mid-cap market space.

17:33 EST First Capital increases quarterly cash dividend to 27c per share - The board of directors of First Capital declared a quarterly cash dividend of 27c per share of common stock. The dividend will be paid on March 31 to shareholders of record as of March 17.

17:29 EST Cannabis accessories firm Humble & Fume updates quarterly expenses - Humble & Fume reported its second-quarter fiscal 2023 financial and operating results for the six and three months ended December 31. "I want to acknowledge the effort made by our prior leadership team," said CEO Jakob Ripshtein. "The past twelve months was a challenging adjustment period for our business." In Q2, the company saw a quarter-over-quarter revenue increase of 177% in its California cannabis distribution business. Operating expenses decreased by $2M or 30% year over year in the North American accessories and Canada cannabis business and decreased by $3.5M or 27% for the six months year over year. However, increased costs of $4.4M and $8.5M relating to expanding the California cannabis distribution business for three and six months, respectively, offset these savings. "The progress we have made in addressing our inventory concerns is encouraging, but we are confident there is more we can do in this area," said Ripshtein. Gross margin improved to 17.1% compared to 11.9% in Q1 2022, thanks to driving efficiencies in the North American accessories business that reduced overall inventory by 14% or $1.5M. Ripshtein continued, "Our focus on margin-enhancing products and opportunities includes the introduction of a proactive, rigorous approach to address inventory levels further. We will concentrate on high-velocity, margin-enhancing SKUs, which are expected to provide working capital and gross profit benefits." The company's new leadership team is focused on accelerating the growth of the cannabis business, driving change management to develop effective and efficient operations, margin enhancement within the North American accessories business, and prioritizing white-label offerings to deliver a differentiated service to customers that generate accretive margins.

17:25 EST Eldorado Gold sees 2023 gold production 475K-515K oz.

17:18 EST ContextLogic names Joe Yan permanent CEO - ContextLogic announced that interim CEO Joe Yan has been appointed the permanent CEO of Wish, effective February 21. Yan, who has been serving as interim CEO since September 2022, has also been appointed to the company's board of directors.

17:08 EST Beacon targets 2025 net sales of about $9B - Targets net sales CAGR of ~8% from 2021-2025. Targets about $1B in adjusted EBITDA by 2025, averaging double-digit margin from 2021-2025.

17:04 EST Oceaneering sees Q1 adjusted EBITDA at $40M-$50M - The company states: "Given the higher cost of performing offshore work over the past several years, customers are increasingly planning their work to avoid periods of higher weather risk. As a result, we anticipate a first quarter seasonal impact, particularly in our OPG business. Considering this and anticipated project timing leading to higher levels of utilization in the second and third quarters, we are forecasting our first quarter 2023 adjusted EBITDA to be in the range of $40 million to $50 million. At the respective midpoints, our first quarter guidance represents a 43% increase over the comparable period in 2022 and is expected to represent a percentage of our annual EBITDA similar to the prior year. Sequentially, we project higher revenue and operating results in our Manufactured Products segment; lower revenue and operating results in our SSR, IMDS, and ADTech segments; and lower revenue and significantly lower operating results in our OPG segment."

17:00 EST Red River Bancshares raises quarterly dividend by 14% to 8c per share - The cash dividend is payable on March 23, 2023, to shareholders of record as of the close of business on March 13, 2023.

16:58 EST Vir Biotechnology shares fall over 5% after missing quarterly estimates -

16:54 EST AAR Corp. appoints Tracey Patterson as Chief Human Resources Officer - AAR Corp. announced that Tracey Patterson has joined the company as VP and Chief Human Resources Officer. In this position, Tracey will oversee global Human Resources, Communications, and other functions. Patterson joins AAR from Accenture, a publicly traded global professional services company. At Accenture, Patterson led the company's Global HR Operations with a team of 10,000 and complex HR initiatives for Fortune 500 clients.

16:53 EST Beacon targets 2025 net sales of about $9B - Targets net sales CAGR of ~8% from 2012-2025. Targets about $1B in adjusted EBITDA by 2025, averaging double-digit margin from 2021-2025.

16:50 EST Beacon expects 2023 market fundamentals to remain stable - 2023 market outlook: Market fundamentals to remain stable, non-discretionary repair, restoration & re-roofing represents significant portion of demand. Single-family new construction activity expected to be subdued in H1'23. While the recent ABI reading is slightly below 50, booking activity remains healthy & backlog provides continued support.

16:43 EST Medical Properties Trust COO McLean to retire - Medical Properties Trust announced that Emmett E. McLean, Executive Vice President, Chief Operating Officer and Secretary, will retire from the company effective September 1, 2023, after more than 20 years of service. "Emmett brought a wealth of experience to MPT from his career in the health care services industry where he served in senior financial positions and we have all benefited from his expertise," said Edward K. Aldag, Jr., MPT's Chairman, President, and Chief Executive Officer. "Beyond his organizational and management skills, Emmett is a great man with a servant's heart. He delights in giving back to his community and his contributions to Birmingham and its surrounding areas are immeasurable."

16:42 EST Essex Property Trust raises annual dividend 5% - Essex Property Trust announced that its Board of Directors has approved a 5.0% increase to its annual cash dividend. This represents the Company's 29th consecutive annual dividend increase. The Board of Directors has declared a first quarter dividend of $2.31 per share, payable on April 14, 2023 to shareholders of record as of March 31, 2023. On an annualized basis, the dividend represents a distribution of $9.24 per common share.

16:40 EST Turning Point Brands raises quarterly dividend 8% to 6.5c per share - The Board of Directors of Turning Point Brands declared a regular quarterly dividend of $0.065 per common share. This is an 8% increase over the regular quarterly dividend declared in November 2022. The dividend is payable on April 7, 2023, to shareholders of record on the close of business on March 17, 2023.

16:39 EST BayCom raises quarterly dividend 100% to 10c per share - BayCom announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share on the Company's outstanding common stock, which represents an increase of 100% over the $0.05 per share quarterly dividend declared on November 16, 2022. The cash dividend will be payable on April 14, 2023 to shareholders of record as of the close of business on March 10, 2023.

16:38 EST Radian Group names Sumita Pandit chief growth officer - Radian Group announced that Sumita Pandit has been appointed Senior Executive Vice President and Chief Growth Officer effective March 6, 2023. Reporting to Radian's Chief Executive Officer Rick Thornberry, she will join the company's executive leadership team and lead activities associated with developing and implementing the company's long-term strategic growth plans.

16:31 EST Block sees FY23 adjusted EBITEA at $1.3B vs. $991M in FY22 - The company states: "Based on trends in our business year to date as of earnings, we expect Adjusted EBITDA margin to expand by at least one percentage point year over year and Adjusted Operating Income margin to also expand on a year-over-year basis in 2023 compared to 2022."

16:30 EST Block sees combined company gross profit in January-February up 25%

16:27 EST Block reports Q4 gross payment volume $48.6B vs. $42.6B last year

16:25 EST TimkenSteel expects to report sequential increase in adjusted EBITDA in Q1

16:23 EST EOG Resources declares regular dividend, $1.00 per share special dividend - EOG's board of directors declared a dividend of 82.5c per share on EOG's common stock. The dividend will be payable April 28, to stockholders of record as of April 14. The indicated annual rate is $3.30 per share. The board of directors also declared a special dividend of $1.00 per share on EOG's common stock. The special dividend will be payable March 30 to stockholders of record as of March 16.

16:22 EST EOG Resources sees 2023 capital expenditures of $5.8B-$6.2B - EOG said: "Total expenditures for 2023 are expected to range from $5.8 to $6.2 billion, including exploration and development drilling, facilities, leasehold acquisitions, capitalized interest, other property, plant and equipment, and excluding property acquisitions, asset retirement costs and non-cash exchanges. The capital program also excludes certain exploration costs incurred as operating expenses. The disciplined capital program is allocated across EOG's high-return, multi-basin drilling portfolio. It is anchored by steady development in the Delaware Basin, with increased activity focused on the Eagle Ford and on EOG's emerging premium plays - the Powder River Basin, South Texas Dorado and Ohio Utica Shale. About $4.4 billion of the capital program is allocated to EOG's existing and emerging premium areas. The capital program also funds investment in international plays, high-potential exploration and environmental and infrastructure projects."

16:21 EST Barings BDC raises quarterly dividend to 25c per share - Record date of March 8 with payment date of March 15.

16:18 EST Floor & Decor reports Q4 SSS up 2.5%

16:14 EST Boeing drops 2% to $204 after WSJ report of halted Dreamliner deliveries

16:11 EST Banc of California announces transition of CFO - Banc of California announced that Lynn Hopkins, Executive Vice President and Chief Financial Officer of the Company and the Bank, would transition from the Company and step down effective March 31, 2023. Raymond Rindone, currently the Company's Deputy Chief Financial Officer and Chief Accounting Officer, has been appointed Interim Chief Financial Officer, effective March 31, 2023. Ms. Hopkins stated, "It has been a tremendous privilege to work with my exceptional colleagues at Banc of California. The work over these last three years has been highly rewarding and I am personally very gratified to have played a key role in transforming the Company to such a large extent. It has also been challenging work, and while exceptionally fulfilling, I look forward to enjoying some welcomed time with my family."

16:10 EST Prothena sees FY23 cash burn of $213-$229M - The Company "expects the full year 2023 net cash used in operating and investing activities to be $213 to $229 million and expects to end the year with approximately $512 million in cash, cash equivalents and restricted cash (midpoint). The estimated full year 2023 net cash used in operating and investing activities is primarily driven by an estimated net loss of $250 to $275 million, which includes an estimated $46 million of non-cash share-based compensation expense."

16:09 EST Farfetch CFO Jordan to step down by end of 2023 - Farfetch announces that Elliot Jordan will step down by the end of 2023, after more than eight years as Chief Financial Officer. The Company will initiate a search process to identify his successor, and Mr. Jordan has agreed to serve as the Company's Chief Financial Officer through the remainder of 2023. Jose Neves, FARFETCH Founder, CEO and Chairman, said: "Elliot has been a fantastic CFO, and I very much appreciate his continued commitment to the business until the end of the year. I look forward to working with Elliot to ensure a smooth transition. We are some way off from saying our 'goodbyes' but his legacy will be formidable finance and business services teams that are part of a company that we believe is extremely well placed to continue to lead the industry and drive profitable growth - and Elliot has been an important building block of our success."

16:08 EST Xencor expects cash to fund operations through the end of 2025 - Based on current operating plans, Xencor expects to end 2023 with between $425 million and $475 million in cash, cash equivalents, receivables and marketable debt securities, and to have cash to fund research and development programs and operations through the end of 2025.

16:05 EST Kratos Defense sees total FY23 CapEx $45M-$50M - Total estimated capital expenditures for 2023 are expected to be $45 to $50 million, which includes approximately $25 to $30 million for expected capital expenditures related to normal annual maintenance. In addition, the 2023 capital expenditure forecast currently includes expected outlays of $10 to $15 million associated with the continued production of Valkyrie aircraft, including our recent decision to move forward with our second serial production run of 12 next generation Valkyries. Other non-recurring, non-maintenance capital expenditures include expansion of the Company's owned satellite monitoring network and our OpenSpace product of approximately $5 to $7 million, and approximately $4 - $6 million of expected capital investments related to the GBSD program.

16:04 EST Expensify affirms long-term guidance - The company states: "We reaffirm our long term guidance provided in connection with our fourth quarter 2021 results of 25%-35% revenue growth over a multi-year period, which assumes an eventual return to normalcy of the world economy."

16:04 EST Expensify reports Q4 EPS (4c), consensus 7c - Reports Q4 revenue $43.5M, consensus $44.4M. "We had a great year considering the challenging macroeconomic environment. The business continues to grow across multiple areas, despite volatility affecting all businesses but especially SMBs. We are heads down executing our long-term product roadmap, and could not be more excited about what we have in store. Pending an eventual return to normalcy, we remain confident with our long-term growth guidance," said David Barrett, Founder & CEO of Expensify. "I continue to contribute 100% of my salary to the employee stock purchase program and the company has been buying back company stock, so we remain very bullish on the future."

16:00 EST LeMaitre board authorizes $25M buyback

14:50 EST ConocoPhillips Director R.A. Walker buys $618K in company shares - ConocoPhillips Director R.A. Walker disclosed in a regulatory filing that he had purchased 6,000 shares of company stock at $103 per share on February 22, for a total transaction amount of $618,000.

14:45 EST Ivanhoe Mines 'not aware of any company-specific reason' for decline in stock - Ivanhoe Mines announced that the company is not aware of any company-specific reason that might be contributing to the recent decline in the company's share price. Ivanhoe will release its fourth quarter and full-year 2022 financial results on Monday, March 13, the company noted. Reference Link

14:34 EST SEC charges Stiles cousins for insider trading in Kodak stock - The Securities and Exchange Commission announced that it has charged Andrew Stiles for insider trading in the stocks of Eastman Kodak Company (KODK) and Novavax (NVAX) based on nonpublic information related to both companies' planned government partnerships to assist in the fight against COVID-19 at the height of the pandemic. The SEC also charged Andrew Stiles' cousin, Gray Stiles, of Richmond, Virginia, for insider trading in Kodak stock that netted the two more than $1.5 million in illegal profits. In a parallel action, the U.S. Attorney's Office for the Southern District of New York today announced criminal charges against Andrew Stiles and Gray Stiles. "During a time of great turmoil, Andrew Stiles is alleged to have repeatedly abused his position as a government contract consultant to generate illegal trading profits," said Joseph G. Sansone, Chief of the SEC Enforcement Division's Market Abuse Unit. "The SEC remains committed to uncovering and prosecuting those who would attempt to enrich themselves by trading on confidential information about governmental activities." Reference Link

13:33 EST AEP Energy Partners, Lightsource bp sign power contract for 188 MW solar farm - Lightsource bp and AEP Energy Partners have signed a power purchase agreement for a 188 megawatt solar project located in New Carlisle about 10 miles west of South Bend, Indiana. Once complete, the Honeysuckle Solar project will generate enough clean energy annually to power 27,000 U.S. homes and will reduce carbon dioxide emissions by 204,000 metric tons each year. Lightsource bp will finance, build, own and operate the facility and sell the solar energy it generates to AEP Energy Partners under a long-term PPA. Construction of the project has been initiated on site, with commercial operation starting in 2024. South Bend based Inovateus Solar LLC is the construction contractor for the facility, with a focus on utilizing local labor for the mechanical, electrical and civil work on site.

12:51 EST RIV Capital settles application initiated by JW Asset Manangement - RIV Capital announced that it has entered into a settlement agreement that has resulted in JW Asset Management consenting to the dismissal of its application related to the Company's acquisition of Etain, LLC and Etain IP. Under the terms of the settlement agreement, RIV Capital has repurchased for cancellation all RIV Capital Class A common shares currently owned or controlled by JWAM and its affiliates, amounting to 33,733,334 shares, for an aggregate purchase price of $19,625,000. RIV Capital has also reimbursed certain legal expenses incurred by JWAM as part of its application and related matters in the amount of $375,000. RIV Capital funded such amounts with cash on hand. As part of the settlement, JWAM and its affiliated funds have also withdrawn their requisition for a special meeting of the Company's shareholders currently scheduled for June 6, 2023, which meeting will be cancelled by the Company.JWAM filed the application against the Company in May 2022, soon after RIV Capital acquire ownership and control of Etain, LLC and Etain IP, LLC, owners and operators of legally licensed cannabis cultivation and retail dispensaries in the state of New York. In the application, JWAM sought a remedy requiring the JWAM Shares to be repurchased by the Company at a price of C$1.65 per share. The Company also announced that The Hawthorne Collective has advised the Company that the litigation between The Hawthorne Collective, JWAM, Jason Wild and certain related parties of JWAM has been settled. The Hawthorne Collective has advised the Company that under the settlement, in return for a withdrawal of the existing litigation and other consideration, Jason Wild and JWAM have agreed, among other things, not to take any action that would interfere with The Hawthorne Collective's agreements with the Company, or any rights set forth in those agreements.

12:33 EST Chubb board to recommend dividend increase to 86c from 83c - Chubb announced that its board will recommend to shareholders at the company's annual meeting an increase in its quarterly dividend. The proposal calls for a $3.44 annual per share dividend, payable in four quarterly installments of 86c per share, compared to the current quarterly dividend amount of 83c per share. The board also declared a quarterly dividend equal to 83c per share, payable on April 10, to shareholders of record at the close of business on March 17.

12:01 EST Coherent begins trading on NYSE - Coherent announced the completion of the transfer of the listing of its common stock and its 6.00% Series A Mandatory Convertible Preferred Stock to the New York Stock Exchange from The Nasdaq Stock Market LLC. The company's common stock and 6.00% Series A Mandatory Convertible Preferred Stock ceased trading on Nasdaq at the close of trading on Wednesday, February 22, 2023. The Company's common stock and 6.00% Series A Mandatory Convertible Preferred Stock began trading on the NYSE on Thursday, February 23, 2023, under the ticker symbols of "COHR" and "IIVI", respectively. "It is exciting for us at Coherent to join the NYSE, one of the world's most prestigious trading platforms. Our company has undergone a tremendous period of transformation, and this move is part of that," said Dr. Vincent D. Mattera, Jr., Chair and CEO. "We look forward to a fruitful relationship as our company continues to grow and we deliver greater shareholder value, and we thank the Nasdaq for their support since our IPO in 1987."

12:00 EST Dutch Bros falls -15.5% - Dutch Bros is down -15.5%, or -$5.88 to $32.11.

12:00 EST Wayfair falls -25.3% - Wayfair is down -25.3%, or -$12.59 to $37.22.

12:00 EST Gannett rises 18.6% - Gannett is up 18.6%, or 48c to $3.06.

11:45 EST Boeing sees completing new-build production of F/A-18 Super Hornet in late 2025 - Boeing announced that it expects to complete new-build production of the F/A-18 Super Hornet fighter aircraft in late 2025 following delivery of the final U.S. Navy fighters. "Production could be extended to 2027 if the Super Hornet is selected by an international customer," the company said. "We are planning for our future, and building fighter aircraft is in our DNA. As we invest in and develop the next era of capability, we are applying the same innovation and expertise that made the F/A-18 a workhorse for the U.S. Navy and air forces around the world for nearly 40 years," added Steve Nordlund, Boeing Air Dominance vice president and St. Louis site leader.

11:04 EST Keysight Technologies acquires Cliosoft, terms not disclosed - Keysight Technologies has acquired Cliosoft and will be adding the company's line of hardware design data and intellectual property management software tools to its portfolio of electronic design automation solutions Since its inception, Cliosoft's primary focus has been managing design data, including functional IP blocks used in integrated circuits. Cliosoft's products expand Keysight's EDA software offering to include process and data management capabilities that have been adopted by more than 400 global semiconductor and electronics systems customers. By bringing Cliosoft into its EDA business, Keysight boosts its intelligent automation software offerings with PDM as an essential component in building the foundation for more productive workflows. Keysight is extending Cliosoft's capabilities to include test data in a fabric that provides customers with a much stronger link between design and test. Keysight and Cliosoft are long-standing industry collaborators as Cliosoft SOS, a data management platform, already integrates with Keysight's Advanced Design System solution which many mutual customers currently use. The combined companies will continue to offer revision control and data and IP management solutions through EDA industry relationships, including Cadence, Empyrean, MathWorks, Siemens EDA, Silvaco, and Synopsys environments. This transaction has no material impact on Keysight's guidance for the current quarter and/or fiscal year. Terms of the transaction have not been disclosed.

10:41 EST Verde Clean Fuels Inc trading resumes

10:31 EST Assured Guaranty establishes indirect subsidiary AG Analytics - Assured Guaranty has established a new indirect subsidiary, AG Analytics, that is developing a new municipal fintech platform for asset management firms, banks, insurance companies, and municipal advisors. The AG Analytics platform plans to offer best-in-class technology and turnkey solutions to replace fragmented data resources now in use by municipal asset managers, analysts and other market participants. Justin Land will be leading this effort as CEO of AG Analytics. The AG Analytics platform will incorporate a dynamic data-driven tool that analyzes obligor level risk and resilience for the public finance industry, which Assured Guaranty will utilize to evaluate the potential risks to obligors in its insured portfolio. In addition to making this tool available to others in the market, AG Analytics will continue to evolve its platform to encompass a wide range of fintech tools to streamline data-intensive analysis for municipal professionals.

10:31 EST Ansys spikes 12% after quarterly results, guidance higher than analyst estimates - Simulation software firm Ansys is up 12 % or $31.27 to $298.06 after announcing Q4 results and guidance that came in ahead of analyst estimates on Wednesday evening.

10:21 EST Golden Falcon Acquisition Corp trading resumes

10:18 EST VBL Therapeutics jumps 60% after announcing merger pact with Notable Labs - VBL Therapeutics is currently up over 50% or 6c to almost 20c per share in morning trading on Thursday. VBL Therapeutics and Notable Labs announced they have entered into a definitive merger agreement. The combined company will focus on the advancement of Notable's proprietary Predictive Precision Medicines Platform and therapeutic pipeline focused on cancer patients with high unmet medical needs.

10:08 EST Creatd appoints Bates to CEOBLOC advisory board - Creatd, the parent company of retail investor activist group CEOBLOC, announced the appointment of Dan Bates, CEO of Clean Vision Corporation to its Advisory Board. Bates joins the two inaugural members of CEOBLOC's advisory board: Jeremy Frommer and Martin Shen.

10:04 EST Air Canada, United to offer over 260 daily transborder flights this summer - Air Canada (ACDVF) and United Airlines (UAL) announced that, through their enhanced transborder joint business agreement, they will offer industry leading capacity and new routes between Canada and the U.S. for summer 2023 - including a new United-operated flight between Washington-Dulles and Calgary and a new Air Canada-operated flight between Washington-Dulles and Vancouver. The carriers have collaboratively optimized their schedules, subject to applicable government and regulatory conditions, and added more flights to provide customers greater connectivity and more flexible flight times, with over 80 transborder codeshare routes and more than 260 daily flights.

10:00 EST Anywhere Real Estate falls -12.9% - Anywhere Real Estate is down -12.9%, or -94c to $6.37.

10:00 EST Unity falls -13.2% - Unity is down -13.2%, or -$4.99 to $32.86.

10:00 EST Joby Aviation rises 13.3% - Joby Aviation is up 13.3%, or 57c to $4.86.

09:47 EST Domino's Pizza falls -10.2% - Domino's Pizza is down -10.2%, or -$35.46 to $313.00.

09:47 EST Amwell falls -16.0% - Amwell is down -16.0%, or -58c to $3.04.

09:47 EST TechnipFMC rises 11.2% - TechnipFMC is up 11.2%, or $1.48 to $14.70.

09:46 EST ESM Acquisition Corp trading halted, news pending

09:40 EST Golden Falcon Acquisition Corp trading halted, news pending

09:35 EST MYR Group trading resumes

09:27 EST IDT Corp introduces Zendit platform - IDT Corporation announced the launch of its cloud-based prepaid-as-a-service platform, Zendit. Zendit will be introduced at the Mobile World Congress 2023 in Barcelona, Spain, from February 27th to March 2nd. With the Zendit platform, businesses of all sizes, entrepreneurs, and developers will be able to easily add a powerful, global monetization channel to their apps and websites - prepaid offerings curated from a global digital catalog of over 10,000 goods and services including mobile airtime top-ups, mobile data bundles, digital gift cards, and utilities.

09:20 EST EzFill named Arbour to board of directors - EzFill has named Daniel Arbour to its Board of Directors. In addition, Arbour will provide Consulting Services in which he will act as the Company's outsourced Chief Revenue Officer. Reporting to EzFill CEO Mike McConnell, Arbour will have oversight of the Company's technology team, as well as sales and marketing to develop go-to-market strategies, pricing strategies and business models. Arbour brings more than 16 years of experience building multi-disciplinary high performance work teams and working to ensure corporate and organizational deliverables are established, most recently as the Principal and Founder of Mountain Views Strategy, a high-level management consulting firm.

09:18 EST Pineapple Energy announces progress on new-build housing strategy - Pineapple Energy announced that its subsidiary SUNation was awarded a contract with a major New York State real estate developer to outfit sustainable homes, demonstrating early traction in its strategy to enter the new-build housing market. Partnering with Baiting Hollow Development Group, SUNation plans to initially outfit 29 homes with solar, battery storage, EV charging, and energy management controls. These "net zero energy ready" homes will be built in one of the first sustainable housing developments in the region, on the north shore of Long Island in New York State. Pineapple Chief Executive Officer Kyle Udseth commented, "This is a great example of Pineapple's commitment to delivering a great customer experience and enabling environmental sustainability. To be selected as the sole clean energy provider for an entire housing development is a huge win for SUNation. This is a testament to the quality of our product offering and our reputation for white-glove customer service. This win confirms one of the reasons Pineapple partnered with SUNation...together we are committed to making an impact on the future of clean energy, and it literally starts at home."

09:16 EST LPL Financial appoints Lopez as EVP of Independent Advisory Services - LPL Financial (LPLA) announced that Julian Lopez has joined the firm as executive vice president, EVP, of Independent Advisor Services Relationship Management, effective February 21. He reports to Matt Enyedi, LPL Financial managing director, Client Success, and is based in College Station, TX. Lopez joins LPL from Charles Schwab (SCHW), where, over a 22-year period, he held several leadership roles, most recently as managing director of the Relationship Management team.

09:14 EST LiveOne says PodcastOne valued betwen $230M-$274M - LiveOne received an independent, third party valuation from ValueScope, which indicates that the fair market value range of its wholly-owned subsidiary PodcastOne's equity, on a controlling, marketable interest basis, as of December 31, 2022, is reasonably stated as between $230 million and $274 million. The valuation report was obtained in connection with LiveOne's planned spin-out of PodcastOne as a separate publicly-traded company to be listed on a national exchange. Separately, LiveOne is extending the record date to March 10, 2023 to determine LiveOne's shareholders eligible to receive the planned special dividend of a portion of PodcastOne's common stock as part of LiveOne's intention to spin-out PodcastOne as a separate public company. The Company will announce the payment date of the planned special dividend subsequent to receiving from the SEC notice of effectiveness with respect to PodcastOne's registration statement previously filed on Form S-1 with the SEC, as well as obtaining final regulatory approvals. Other criteria to determine LiveOne's shareholders of record eligible for the special dividend shall be determined and announced by LiveOne at a later date. The planned spin-out, amount of the special dividend and LiveOne's shareholders' dividend eligibility shall be subject to obtaining applicable approvals and compliance with applicable rules and regulations and public market trading and listing requirements.

09:13 EST AgriFORCE Growing granted patent from USPTO related to FORCEGH+ facilities - AgriFORCE Growing Systems announced it was granted a patent from the United States Patent and Trademark Officer, USPTO, titled "Structures for Growing Plants," relating to its FORCEGH+ facilities. This granted patent is among a group of applications the Company has submitted related to its FORCEGH+ facilities for controlled environment agriculture. Specifically, this granted patent has 19 claims relating to the unique features and design of its structures for growing plants including transmissive panels that maximize the full light spectrum, enhanced insulation for maximizing energy efficiency, and innovative formation of structure support materials. "This granted patent marks another milestone for AgriFORCE and further strengthens our patent portfolio in key markets," commented Ingo Mueller, Chief Executive Officer of AgriFORCE. "We believe our unique designs and technologies, deployable in virtually any climate or geography, have the potential to set a new industry standard for higher quality and higher yield crops and anticipate additional patents to be granted related to our FORCEGH+ facilities."

09:13 EST Delta in extended pact with IT infrastructure firm Kyndryl for IT resiliency - Kyndryl (KD) announced a 5-year extended agreement with Delta Air Lines (DAL) to enhance IT resiliency and scalability. Through the extended agreement, Kyndryl will continue to help Delta run the core systems that power the airline's essential operations, including crew rostering and scheduling, as well as the system that supports Delta's maintenance documentation process. Kyndryl also supports Delta's major customer relations and loyalty programs and Delta's software for rebooking passengers from cancelled flights. With air travel near pre-pandemic levels, Delta relies on IT infrastructure with flexibility to scale and meet fluctuations in customer demand on more than 4,000 daily flights across its global network. With the support of Kyndryl, Delta continues to provide industry-leading reliability and service, and it can advance how its data is harnessed for innovation in the future.

09:12 EST Biora Therapeutics announces bioavailability results for oral delivery of GLP-1 - Biora Therapeutics announced preliminary results from preclinical testing of its PGN-OB2 program, reporting an average bioavailability of 37% for semaglutide, a GLP-1 receptor agonist. Semaglutide is currently marketed as two subcutaneously administered formulations under the brand names Ozempic for the treatment of diabetes and Wegovy for weight management. An oral formulation of a GLP-1 molecule that uses a different delivery technology, brand name Rybelsus, is also currently marketed for the treatment of diabetes, with studies demonstrating bioavailability of less than 1%. "These results demonstrate the potential of our oral liquid jet delivery technology to deliver multiple large molecules, with first a monoclonal antibody, as we announced recently, and now a peptide both exceeding a bioavailability target of 15% set by us and our pharma collaborators for progression of the platform," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "With strong patent protection for our liquid jet delivery platform and methods to deliver a range of drugs, including a patent that covers jet delivery of any GLP-1 receptor agonist to the small intestine, our work continues toward finalizing this next-generation device over the coming months and subsequently progressing our pharma collaborations." Biora's PGN-OB2 preclinical study included a single dose of a liquid formulation of 0.96 mg of semaglutide, a GLP-1 receptor agonist. Eight animals were dosed using the liquid jet delivery device, which was administered and activated endoscopically, as is typical in a porcine model, with comparison to a control animal with drug administered intravenously. The company expects to release detailed results in conjunction with planned presentation of the data.

09:11 EST Neuronetics expands NeuroStar Advanced Therapy's TrakStar platform - Neuronetics announced its first of several TrakStar Patient Data Management System software releases this year. In conjunction, the Company is launching a new educational campaign called "Get There FASTER with TrakStar," which will encourage current and new NeuroStar providers to unlock all the potential features of TrakStar. "It's vitally important for providers to help their patients access treatment as soon as possible when they need it. TrakStar is the only tool of its kind that allows NeuroStar providers to seamlessly connect with and manage patients throughout their treatment process," stated Cory Anderson, VP of R&D and Clinical. "As we continue to invest in TrakStar this year, the new campaign will highlight the current and future benefits it brings to our NeuroStar providers and their patients."

09:08 EST Agora launches 3D Spatial Audio - Agora announced the launch of Agora 3D Spatial Audio, a solution that allows developers to add immersive, dynamic audio into real-time digital experiences. With a few lines of code, developers can connect to Agora's 3D Spatial Audio to enable a more natural audio experience that works seamlessly with video, voice, and streaming products, replicating how sounds are heard in the real world and boosting user engagement.

09:07 EST Verses Technologies announces General Intelligent Agent, codenamed GIA - VERSES Technologies announced a breakthrough in AI with the world's first General Intelligent Agent, codenamed GIA, designed to offer a new human-centered way for businesses and individuals to interact with technology. GIA, a General Intelligent Agent, is a next-generation personal AI assistant that is designed to learn about its users in order to better organize, manage, and optimize their digital life. GIA, the smart interface to the digital world, is a voice and text-based digital assistant that operates under a user's direction and on their behalf, searching, filtering, and summarizing information across multiple data sources. With unique features like automating data organization, predictive reasoning, and the ability to learn over time, GIA is poised to become the first intelligent all-in-one solution for anyone seeking a smarter way to organize, manage, and automate their personal and professional activities.

09:05 EST Remitly Global expands into the Middle East with UAE launch, Dubai office - Remitly Global announced it has expanded into the Middle East with the launch of its outbound remittance product in the United Arab Emirates, UAE. Remitly has also opened an office in the Dubai International Financial Center, DIFC, its first in the country. "With one of the world's largest populations of immigrants and the second-highest global volume of remittance originations, the UAE was a natural choice for us as a market for expansion," said Mohamed Mansour, Head of Region, UAE at Remitly. "Moreover, the country's advanced digitization and push towards a cashless economy makes Remitly's platform particularly relevant and well suited to the population here. I'm thrilled that this expansion will bring reliable international payments support for immigrants and their loved ones back home."

09:04 EST Shuttle Pharmaceuticals expands laboratory space for drug pipeline - Shuttle Pharmaceuticals has entered an agreement to lease new laboratory and office space, commencing in June, to complement the development of the company's lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers. The new laboratory space, located in Gaithersburg, Maryland, is located within the Maryland Biotech Corridor.

09:02 EST Nikola provides 2023 outlook - The company said, "We plan to achieve the following milestones in 2023: Complete the build of 10 gamma FCEVs by Q2 2023; Realize approximately $105,000 in cost savings in battery modules and packs for each Tre BEV truck by Q4 2023; Achieve Final Investment Decision for the Phoenix Hydrogen Hub by Q3 2023; Announce at least two refueling station partners by June; Deliver 250 - 350 Tre BEVs to dealers for the Full Year 2023; Deliver 125 - 150 Tre FCEVs in Q4 2023.

08:59 EST Ensysce Biosciences CEO says mindful of potential shareholder dilution - Ensysce Biosciences issued a letter to shareholders from CEO Lynn Kirkpatrick, to address the Company's most recent frequently asked questions. The letter read in part, "What is the next Company milestone? As noted above in 2022 Ensysce initiated four clinical studies: PF614-102 for bioequivalence. PF614-103 evaluating nasal abuse potential. PF614-104 evaluating oral abuse potential. PF614-MPAR-101 evaluating our overdose protection platform, MPAR. We have reported positive results on three of these studies, and we are currently awaiting data from our oral abuse potential study, PF614-104, at the end of March. What does the Ensysce pipeline look like? Our lead product, PF614 is an oxycodone product for severe pain to go head-to-head with the current ADF products on the market. Our MPAR combination products provide overdose protection to our TAAP portfolio. PF614-MPAR will follow the launch of PF614. These two products offer improved oral delivery of oxycodone, reduced abuse potential and, ultimately, overdose protection. We believe we can use our TAAP platform to improve other prescription drugs and have a number of other clinical candidates identified to be rolled out as we progress. We are exploring these opportunities....As of September 30, 2022, we reported $4.5 million in cash on hand and $5.8 million of remaining federal government grant support. Recent financing transactions include a $4.1 million public offering in December 2022 and a $3.0 million registered direct offering in February 2023. We will be reporting our updated cash position as of December 31, 2022, with our Form 10-K filing in March 2023. Why has the share price not responded as planned? While we do not believe it is appropriate to speculate as to why the share price performance is not stronger, despite our continued execution against our developmental plans, we want to express our disappointment. We cannot control the stock market and therefore are focused on the variables of our business that we can control. As a result, we hope that our continued diligence and execution translates to value that is ultimately reflected in our share price. We remain committed to our mission, to helping people in pain, and to our shareholders. Should we be worried about further dilution or the Company's cash position? Ensysce is a pre-revenue, clinical stage biotech company. As we advance our clinical development toward commercialization, our cash burn is expected to increase. We believe we have made exceptional strides to advance our programs with limited financial resources. We are mindful of market conditions and have been thoughtful with our sources for funding, including the use of non-dilutive financing through grants from the federal government. Committed long-term shareholders are our most important constituent right now. Hence, we are constantly looking for the best opportunity for capital, while being mindful of potential shareholder dilution."

08:55 EST Halliburton and Siguler Guff announce JV for emissions management software - Halliburton and Siguler Guff & Company announced the launch of Envana Software Partners, . The new venture provides critical emissions management software-as-a-service solutions to track greenhouse gas emissions in the oil and gas industry and beyond. The Envana digital emissions management solution provides a smarter and more accurate picture of emissions, which gives companies actionable information to manage and reduce their total carbon footprint. The Halliburton-created software incorporates the company's operational expertise and oilfield best practices. Future Envana products that are now in active development will support methane detection and quantification management. The venture's first offering, Envana Catalyst, is a SaaS solution that helps increase transparency of the environmental impact of drilling, completions, and production operations. It can improve the visibility of greenhouse gas emissions tracking and forecasting companywide and can provide support for actionable recommendations throughout upstream asset life, from planning and design through execution. Envana Catalyst allows customers to choose the methodologies used to estimate emissions from a library of emissions sources tailored to the oil and gas industry, update them as needed, and track any changes.

08:54 EST Central Puerto acquires Central Costanera for $48M - Central Puerto acquired Central Costanera for $48M. By taking possession of Central Costanera, Central Puerto will add an installed capacity of 2,305 MW -to its already 4,809 MW- and thus will contribute a total of more than 7,100 MW to the Argentine Interconnection System. After closing this operation, Osvaldo Reca was appointed as the new president of Central Costanera. With the incorporation of Central Costanera, the company will reach, together with its assets, a participation of 17% of the total generation capacity of Argentina. Central Costanera is located in the City of Buenos Aires, reaching almost 6% participation in the total installed capacity of SADI and generates the energy demanded by 3.5 million homes throughout the country. Currently, the Costanera plant is made up of six turbo-steam units, with an installed capacity of 1,140 MW of power, and two Combined Cycle units of 315 MW and 850 MW. To this is added 35.6 MW in relation to the purchase of engines from the El Chocon hydroelectric plant.

08:51 EST Eskay Mining announces diamond drill results from Consolidated Eskay Property - Eskay Mining announced further diamond drill results from its 2022 exploration program at its 100% controlled Consolidated Eskay Property in the Golden Triangle, British Columbia. "Results from our 2022 exploration season demonstrate Eskay's team has made considerable progress toward unraveling the district-scale potential of VMS mineralization surrounding the Eskay Creek deposit," commented Dr. John DeDecker, VP of Exploration for Eskay Mining Corp. "Achievements of the 2022 exploration program include defining a new trend of VMS mineralization along the Scarlet-Tarn corridor parallel to and approximately seven kilometers east of the Eskay anticline. Tarn Lake and Scarlet Knob are situated along an east-west trending VMS feeder structure hosted by Eskay rhyolite like that seen in the footwall of the Eskay Creek deposit. Mapping and prospecting define a westward stratigraphic younging direction suggesting that stockwork and replacement-style mineralization at Tarn Lake may represent feeders to seafloor-hosted mineralization up-section towards the important Contact Mudstone horizon, host to high-grade mineralization at Eskay Creek. This recognition is a significant step towards meeting our goal of discovering new Eskay Creek-like high-grade VMS systems. Drilling at TV now shows that Au- and Ag-bearing massive sulfide extends 100 m along strike and overlies an even more extensive zone of stockwork mineralization. We are eager to follow up on all of these encouraging results in 2023." TV Extensional Drilling: Highlight results: 4.61 gpt Au and 22.17 gpt Ag over 6.28m within 2.84 gpt Au and 22.17 gpt Ag over 16.36m in hole TV22-105; 2.66 gpt Au and 30.45 gpt Ag over 10.56m within 1.51 gpt Au and 25.39 gpt Ag over 43.09m in hole TV22-120; 3.36 gpt Au and 109.50 gpt Ag over 2.00m within 1.14 gpt Au and 30.40 gpt Ag over 30.56m in hole TV22-97; 6.88 gpt Au and 21.00 gpt Ag over 1.10m within 1.28 gpt Au and 87.92 gpt Ag over 14.95m in hole TV22-109.

08:48 EST Jeffs' Brands enters agreement to acquire 49% of SciSparc Nutraceuticals - Jeffs' Brands (JFBR) announced that it has entered into a definitive agreement with SciSparc (SPRC), to purchase from it approximately 49% of the outstanding capital stock of SciSparc Nutraceuticals, a wholly-owned subsidiary of SciSparc that owns Wellution for $2.5 million in cash. The stock interest of Jeffs' Brands in the Subsidiary is expected to be held by a wholly-owned Delaware subsidiary of Jeffs' Brands. In addition, the Agreement also includes a mutual share exchange between SciSparc and the Company of restricted shares in the total amount of $300,000. The number of shares in the share exchange will be calculated based on the average closing price of the relevant company's shares for 30 consecutive trading days ending on the third trading day immediately prior to closing the transaction. The closing of the transaction is subject to certain customary conditions and is expected to be completed within seven business days. At closing, the Company and the Subsidiary will enter into a consulting agreement by which the Company will provide management services for the Brand for a monthly fee of $20,000. The agreement is for an undefined period of time, and may be terminated by either party with 30-days' advance notice. The Brand is profitable with millions of dollars in gross annual sales on the Amazon market place. The Brand sells dozens of hemp-based, top-ranked products, including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States The Brand offers eight variations of natural hemp candy supplements under two parent Amazon Standard Identification Number on Amazon that are differentiated by their hemp oil potency. The leading parent ASIN, that was launched in 2019, has received over 26,500 reviews and has consistently ranked as the #1 best seller in the category. In total, the Brand had approximately 40,000 product reviews to date, most of which are 4 and 5-star reviews. Mr. Oz Adler, the Chairman and a director of the Company is the Chief Executive Officer and Chief Financial Officer of SciSparc, Mr. Amitai Weiss, the Chairman of SciSparc, is a director of Jeff's Brands, and Mr. Moshe Revach is a member of the board of directors of the Company and SciSparc.

08:46 EST Fiserv announces 75M share repurchase authorization - Fiserv announced that its board of directors has authorized it to repurchase 75M shares of the company's common stock, which is in addition to the shares remaining available under the company's existing authorization.

08:45 EST Snail announces Wandering Wizard to showcase latest games at PAX East 2023 - Snail announced that its indie publishing sub-label, Wandering Wizard, will be showcasing its latest Early Access games, West Hunt and Expedition Agartha, at PAX East 2023 in Boston, Massachusetts from March 23 to 26, 2023. Jim Tsai, Chief Executive Officer of Snail, commented: "We are thrilled that Wandering Wizard will be attending PAX East 2023, and we look forward to engaging with the gaming community. Our team at Wandering Wizard is dedicated to creating engaging and immersive experiences for players, and we are committed to listening to feedback and suggestions from our players to make our games even better. Following Wandering Wizard's successful appearance at PAX West 2022, we are excited to showcase the latest games at the upcoming PAX East 2023 and build on the momentum we've achieved thus far."

08:42 EST Mobile Global Esports lauches India Esports Campus Ambassadors Program - Mobile Global Esports announced the official launch of the MOGO Campus Ambassadors program. 138 students have signed on as MOGO campus ambassadors at their respective colleges and universities to drive forward their competitive gaming and industry aspirations while creating a grassroots collegiate esports outreach network across India.

08:40 EST Nocera purchases 229 acres of land in Montgomery, Alabama - Nocera announced that on February 16, 2023, it closed on its $875,000 purchase of 229 acres of agricultural land in Montgomery, Alabama, of which was funded through available cash of $225,000 and loan proceeds of $650,000 from an unaffiliated Taiwan financial company. Nocera plans to use the land to construct its first large scale fish farm designed to use its RASs and tanks. The Company plans to begin site preparation and construction by the third quarter of this year. The site is expected to serve as a model for future construction and is the first of many facilities that Nocera plans to launch.

08:38 EST InterDigital announces final results for tender offer - InterDigital announced the final results of its modified "Dutch auction" tender offer to purchase up to $200 million of its common stock for cash at a price per share not less than $65.25 and not greater than $75.00, which expired at 11:59 p.m., New York City time, on February 17, 2023 Based on the final count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, InterDigital has accepted for purchase 2,739,726 shares of its common stock at a price of $73.00 per share, for an aggregate cost of approximately $200 million, excluding fees, expenses and excise tax relating to the tender offer. The repurchased shares represent approximately 9.2% of the Company's shares outstanding as of February 17, 2023. As such, the Company has been informed by the depositary that the final proration factor for the tender offer is approximately 95.80%. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, will promptly issue payment for the shares of InterDigital common stock validly tendered and accepted for purchase in the tender offer, and will return all other shares tendered and not purchased in the tender offer.

08:37 EST Sunrun sees FY23 installed growth up 10%-15% - As part of its Q4 results yesterday, the company stated: "Management's focus is on leading the market through sustainable and profitable growth, prioritizing unit cash generation capabilities, while prudently managing working capital needs. Management expects Solar Energy Capacity Installed growth to be in a range of 10% to 15% for the full year 2023. Management currently sees more upside opportunity than downside risk to achieving growth in this range and anticipates market share gains in 2023. Management expects Solar Energy Capacity Installed growth to be in a range of 215 to 225 Megawatts in the first quarter of 2023. Management expects to update the discount rate assumption used to calculate Subscriber Value, Gross Earning Assets and Net Subscriber Value from 5% to 6%, commencing with the first quarter 2023 reporting. As such, Net Subscriber Value guidance is being provided assuming a 6% discount rate. Net Subscriber Value is expected to be approximately $10,000 in the first quarter and to increase sequentially throughout 2023."

08:36 EST Predictive Oncology announces partnership with Cvergenx - Predictive Oncology and Cvergenx announced an agreement to form a strategic partnership that to develop the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery. The objective of this collaboration will be to leverage and maximize the combined power of their respective proprietary technologies and domain expertise for a common purpose. By applying Predictive Oncology's drug discovery, artificial intelligence and machine learning capabilities, and the Cvergenx precision genomics radiation therapy platform, the two companies will pursue ways in which to optimize radiotherapy to improve patient outcomes in a way that has never been done before. "The central principle in precision medicine is that cancer therapy should be tailored to the individual tumor biology. Even so, radiation therapy, the most commonly utilized therapeutic agent in clinical oncology, has yet to enter the era of precision therapy," said Raymond Vennare, Chief Executive Officer of Predictive Oncology. "We believe that the next and most significant paradigm shift in the field of radiation oncology will come from exploiting tumor genomics to optimize RT prescription dose and to identify drug targets for the development of radiosensitizers and radioprotectors for biopharma and industry."

08:35 EST Evofem to explore and evaluate strategic alternatives - Evofem Biosciences announced that its Board of Directors has unanimously approved a comprehensive strategic process to explore and evaluate strategic alternatives to maximize shareholder value. Potential strategic alternatives to be explored or evaluated as part of this process may include, but are not limited to, a merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the company. Evofem does not expect to disclose developments with respect to this process unless until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.

08:34 EST SciSparc to sell 49% interest in subsidiary to Jeff Brands subsidiary for $2.5M - SciSparc (SPRC) announced it has signed a definitive agreement to sell a 49% interest in its wholly owned subsidiary, SciSparc Nutraceuticals, which owns Wellution, to a wholly-owned subsidiary of Jeffs' Brands (JFBR), for $2.5M in cash, subject to certain purchase price adjustments related to inventory and working capital expected to increase the purchase price by approximately $300,000, plus a mutual share exchange in the amount of $300,000 of ordinary shares from each of SciSparc and Jeffs' Brands. The number of shares in the share exchange will be calculated based on the average closing price of the relevant company's shares for 30 consecutive trading days ending on the third trading day immediately prior to closing the transaction. Following the closing of the transaction, which includes an equity conversion of financing amounts previously provided to the Subsidiary by SciSparc, SciSparc will hold approximately 51% of the Subsidiary. Closing of the transaction is subject to certain customary conditions and is expected to be completed within seven business days. At closing, Jeffs' Brands and the Subsidiary will enter into a consulting agreement by which Jeffs' Brands will provide management services for Wellution for a monthly fee of $20,000. The agreement is for an undefined period of time and may be terminated by either party with 30-days' advance notice. "The agreement expands our collaboration with Jeffs' Brands for the online marketing and sale on Amazon of food supplement products following our recent letter of intent signed with Jeffs' Brands for the development of a new food supplements product line and the online marketing of such supplements. We are pleased to have Jeffs' Brands as our partner which we believe will strengthen the Wellution brand," said Oz Adler, Chief Executive Officer of SciSparc.

08:34 EST Noranda Income Fund announces support agreements with unitholders - Noranda Income Fund announced that Glencore Canada Corporation has agreed to increase the purchase price for the acquisition of all issued and outstanding priority units of the Fund from $1.42 to $1.98 per priority unit and the parties have entered into an amending agreement to amend the arrangement agreement dated January 8, 2023 accordingly. The purchase price of $1.98 per priority unit represents a 102% premium on the closing price on the Toronto Stock Exchange on January 6, 2023, the last trading day prior to announcement of the Arrangement Agreement, and a 126% premium on the 20-day volume weighted average price per priority unit on the TSX for the period ending on January 6, 2023. Prior to the Fund entering into the Arrangement Agreement on January 8, 2023, Accuracy Canada provided an independent valuation to the Independent Committee of the Board of Trustees of Noranda Operating Trust, which determined that, as at December 31, 2022, based upon and subject to the assumptions, limitations and qualifications contained therein, the fair market value of the priority units ranged from $1.24 to $1.94 per unit. The increased purchase price of $1.98 per unit exceeds the top-end of this valuation range. Glencore has also entered into lock-up and support agreements with Riverstyx Capital Management, LM Asset Fund Limited Partnership, LM Asset Management, Daniel Lau and Doug Warwick, who in the aggregate beneficially own or have control or direction over 8,337,691 priority units or approximately 22% of the priority units of the Fund. Under the terms of their Support Agreements, the Supporting Unitholders have agreed to support and vote all of the priority units of the Fund they control at the special meeting of Fund unitholders to be held on February 28, 2023, or at any adjournment or postponement thereof, in favour of Glencore's acquisition of the Fund by way of plan of arrangement, as set forth in the Arrangement Agreement, as amended. The Amending Agreement was unanimously approved by the Board, with those members of the Board who are related to Glencore abstaining from voting, and its Independent Committee. The Arrangement, as amended, is subject to the condition that the Supporting Unitholders comply in all material respects with their obligations, covenants and agreements in their Support Agreements. All other terms and conditions of the Arrangement Agreement otherwise remain unchanged. The Board, with those members of the Board who are related to Glencore abstaining from voting, and its Independent Committee unanimously reiterate that the Arrangement with Glencore is in the best interests of the Fund and its priority unitholders and is fair to the Fund priority unitholders, and unanimously recommend that priority unitholders: Vote FOR the special resolution approving the Arrangement with Glencore

08:32 EST Nucor provides one-year update on new sheet steel mill in West Virginia - Nucor provided a one-year update on the status of its new sheet steel mill in West Virginia, including the approval by the company's Board of Directors to provide additional capital to fund the construction of the project. The new mill will have an annual capacity of 3M tons per year, and employ as many as 2,000 construction workers during the building phase and approximately 800 full-time teammates when it is fully operational. "We remain incredibly excited about our Nucor Steel West Virginia mill and its advanced capabilities that will expand our ability to provide our customers with the cleanest and highest-quality steel products, particularly for demanding automotive and construction applications," said Leon Topalian, Chair, President and CEO of Nucor Corporation. "The Midwest and Northeast consume half the sheet steel in the United States. This transformative project will provide customers in these high-demand regions with more sustainable sheet steel, create long-term value for our shareholders and fuel additional growth for Nucor." Nucor now expects a net cash outlay of approximately $3.1B for the West Virginia sheet mill, up from $2.7B when the project was first announced in September 2021. The revised $3.1B estimate is net of $275M in cash proceeds received from the State of West Virginia for costs related to the Apple Grove site location. Factors contributing to the increased capital cost include general inflation, the acquisition of additional property and equipment, and expanded port and rail infrastructure requirements. To date, Nucor Steel West Virginia has received all required state permits and is working to secure federal permits this spring. Construction of the new sheet mill is expected to take 2-3 years once all the necessary permit approvals have been received, and Nucor Steel West Virginia is actively hiring teammates to grow its team in the state. When operational, the new mill will be the most capable sheet mill in the region with a significantly lower carbon footprint than its competitors. It will be equipped to produce 84-inch sheet products, and among other features, will include a 76-inch tandem cold mill and two galvanizing lines capable of producing advanced high-end automotive and construction grades. Nucor Steel West Virginia will have a freight advantage and unmatched capabilities that will enable the continued expansion of Nucor's high-quality, low-carbon steel product offerings.

08:32 EST Ocean Biomedical announces discovery of bispecific antibodies - Ocean Biomedical celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%. Recent studies from the laboratory have demonstrated that CHI3L1 is a critical regulator of a number of key cancer-causing pathways. We have highlighted its ability to inhibit tumor cell death, its inhibition of the expression of the tumor suppressors P53 and PTEN and its stimulation of the B-RAF protooncogene. Most recently the company has discovered that CHI3L1 is a "master regulator" of ICPI including key elements of the PD-1 and CTLA4 pathways. In accord with the importance of these pathways we have also generated antibodies: 1.) a monoclonal antibody against CHI3L1, and 2.) bispecific antibodies that simultaneously target CHI3L1 and PD-1 or CTLA4. The impressive ability of our bispecific antibodies to control primary and metastatic lung cancer in murine experimental modeling systems is discussed below. "Non-small cell lung cancer is the leading cause of cancer death and second most diagnosed cancer in the US. Glioblastoma multiforme is a lethal type of brain tumor that affects approximately 28,000 people in the U.S. The median survival time is about 15 months. With our discovery that CHI3L1 is a critical regulator of a number of key cancer-causing pathways by highlighting its ability to inhibit tumor cell death this therapy has the potential to save thousands of lives of people effected from NSCLC and GBM," said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman.

08:29 EST Pacira, LPGA partner to raise awareness of non-opioid pain management solutions - Pacira BioSciences and the Ladies Professional Golf Association, LPGA, announced a multi-year sponsorship that makes Pacira's iovera degrees - a handheld medical device that provides non-medicated pain control by applying cold therapy to a specific nerve to interrupt its ability to transmit a pain signal - the Official Non-Opioid Pain Management Partner of the LPGA. In addition, Pacira will serve as the official sponsor of the LPGA's fitness trailer. LPGA's Medical Director Dr. Thomas Bruce will also make information on non-opioid offerings available to LPGA players. "Our partnership with the LPGA offers us the unique opportunity to educate the golf community at large about the importance of non-opioid options available to treat pain along the care continuum from initial injury, pain progression, and even surgical intervention when necessary," said Dave Stack, Chief Executive Officer and Chairman of Pacira BioSciences, Inc. "We are honored to partner with the LPGA in support of pain management education, and awareness of the role analgesic alternatives like ioveradegrees can play in the overall need for opioids."

08:27 EST Nuwellis announces data on role of ultrafiltration in preventing AKI - A recent editorial published in The Annals of Thoracic Surgery provides additional clinical evidence to support the role that ultrafiltration plays in preventing cardiac surgery-associated acute kidney injury, AKI, according to Nuwellis. Written by Daniel Engelman, M.D. and Andrew Shaw, M.D., "A Turnkey Order Set for Prevention of Cardiac Surgery-Associated Acute Kidney Injury" compares protocols for preventing cardiac surgery-associated acute kidney injury from leading cardiothoracic surgical societies. This topic is of critical importance to cardiac surgeons because as many as 80% of cardiac surgery patients may have stage 1 or greater CSA-AKI, according to guidelines published by Kidney Disease Improving Global Outcomes, the global nonprofit organization developing and implementing evidence-based clinical practices guidelines in kidney disease. The editorial examines the role of intravenous fluid overload in contributing to CSA-AKI and challenges the notion that diuretics are always the best management approach. "We're thrilled to have additional validation for the technology behind Aquadex in this new publication," said Dr. John Jefferies, Chief Medical Officer of Nuwellis. "We often hear about the need for alternatives to diuretics from clinicians. This publication validates ultrafiltration as a best practice when diuretics fall short in treating patients with fluid overload during and after cardiothoracic procedures."

08:26 EST Arisz Acquisition extends deadline for business combination - Arisz Acquisition Corp. announced that Arisz Investments LLC, the Company's initial public offering sponsor, has timely deposited into the Company's trust account, an aggregate of $690,000, in order to extend the period of time the Company has to complete a business combination for an additional three month period, from February 22, 2023 to May 22, 2023. The Extension is the second of up to two three-month extensions permitted under Arisz's governing documents. The Extension provides Arisz with additional time to complete its proposed business combination with Finfront Holding Company.

08:24 EST Elys Game Technology signs agreement to operate sportsbook at The Ugly Mug - Elys Game Technology announces that the Company has entered into an agreement with Partnersat7238thstse to operate a sportsbook at The Ugly Mug restaurant and bar situated at 723 8th St SE, in Washington, DC. "We are delighted to partner with Gaynor Jablonski and his team to operate a sportsbook at The Ugly Mug restaurant and bar conveniently located only blocks from Nationals Stadium in Washington, DC," stated Michele Ciavarella, Elys Executive Chairman. "By fostering partnerships in local establishments such as The Ugly Mug, Elys brings together vibrant environments with a professionally managed sports betting enterprise. This combination can connect fans and friends together to revel in sports events while enjoying a meal and beverage. We firmly believe that this successful combination can contribute economic benefits to small business entrepreneurs across the nation and boost resources for state and local amenities and infrastructure."

08:23 EST Proterra, Thomas Built Buses reach major milestone for electric school buses - Thomas Built Buses, TBB, and Proterra announced that TBB's Proterra Powered Saf-T-Liner C2 Jouley electric school buses have driven more than one million miles for school districts across North America. With more than 300 electric school buses on the road, today's announcement represents a major operational milestone just as historic federal funding, like the EPA's Clean School Bus program, becomes available to drive adoption of zero-emission school buses in the United States. "Surpassing one million miles driven by Proterra Powered electric school buses is a major achievement on the road to an all-electric, emissions-free future. With zero tailpipe emissions, Proterra Powered school buses are contributing to cleaner air and healthier communities. Along with our partners at Thomas Built Buses, we're proud to support the schools and communities across America who are at the forefront of the transition to zero-emission transportation," said Chris Bailey, President of Proterra Powered & Energy.

08:22 EST Ekso Bionics to showcase integrated FES for Indego Therapy at APTA meeting - Ekso Bionics announced it will showcase the new Ekso Indego Therapy with Functional Electrical Stimulation, FES, at the upcoming American Physical Therapy Association's, APTA, Combined Sections Meeting on February 23-25 in San Diego, California. The Company recently filed a Premarket Notification 510(k) with the U.S. Food and Drug Administration that covers the addition of integrated FES hardware and software to Ekso Indego Therapy, a lower-limb powered exoskeleton recently acquired by Ekso. "This unique integrated solution is a testament to Ekso Bionics' continued commitment to innovation and delivering on our promise of maximizing patient outcomes," said Scott Davis, Chief Executive Officer of Ekso Bionics. "Individuals with spinal cord injury or stroke who use Ekso Indego Therapy in a rehabilitation setting will soon have the opportunity to benefit from FES in further improving limb function, balance and muscle strength. We are excited to see the added benefits this technology will bring to patients across the continuum of care."

08:21 EST BioAtla announces FDA clearance of IND for BA3182 - BioAtla announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, application to evaluate BA3182 for the treatment of advanced adenocarcinoma. BioAtla plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study in 2023. "While we continue to advance our CAB-ADC and CAB immuno-oncology antibodies across multiple tumor types, we are now expanding our pipeline with the recent FDA IND clearance for our potentially first-in-class bispecific antibody, BA3182," said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla. "Our goal is to continue executing and pursuing indications with large unmet medical need that potentially have the highest impact for patients and our shareholders worldwide. We believe our current cash position is sufficient to fund our operations into 2025 through several value generating milestones for our current clinical programs as well as the initiation of the BA3182 clinical trial."

08:20 EST NV5 Global announces acquisition of Axim Geospatial - NV5 Global announced that it has acquired Axim Geospatial. Axim expands NV5's capabilities in the federal defense and intelligence sectors and strengthens NV5's leadership position in geospatial utility solutions. "Since first entering the geospatial market in 2017, NV5 has expanded its capabilities in geospatial data analytics, subscription-based geospatial software, SaaS service models, and proprietary, tech-enabled data acquisition to become the nation's leading provider of geospatial data solutions," said Dickerson Wright, PE, Chairman and CEO of NV5. "The acquisitions of Axim and L3Harris' commercial geospatial technology and software business have made NV5 the leader in geospatial solutions for the defense and intelligence community and strengthened NV5's existing federal geospatial team."

08:17 EST GoDaddy announces launch of Payable Domains - GoDaddy announced the launch of Payable Domains, which allow entrepreneurs to register a new domain and easily start accepting payments from customers. GoDaddy is the first company to seamlessly bundle payment technology with the brand power of a professional domain - at no additional cost - to help small business owners start growing from day one.

08:17 EST Wayne Savings, Main Street Financial announce Merger of Equals - Wayne Savings Bancshares and Main Street Financial Services the holding company of Main Street Bank Corp., today announced they have entered into an Agreement and Plan of Merger under which Wayne will merge with and into Main Street in an all-stock transaction valued at approximately $68 million, which equates to $30.53 per Wayne share based on Main Street's stock price of $17.50 as of February 22, 2023. As part of the merger, the operating bank subsidiary of Main Street, Main Street Bank Corp., will merge with and into the operating bank subsidiary of Wayne, Wayne Savings Community Bank. The combined bank will be branded as Main Street Bank. The transaction is expected to be approximately 40% accretive to Main Street's earnings per share on a fully phased-in basis, excluding merger charges and approximately 16% accretive to Wayne's earnings per share on a fully phased-in basis, excluding merger charges, on an exchange ratio-adjusted basis. Main Street also expects to increase its quarterly dividend to approximately $0.13 per share after closing. Under the terms of the definitive agreement, which was unanimously approved by the boards of directors of both companies, holders of WAYN common stock will have the right to receive 1.7446 shares of MSWV common stock. Existing Main Street shareholders will own approximately 47.5% of the outstanding shares of the combined company and Wayne shareholders are expected to own approximately 52.5% of the combined company. The combined company will trade under the Main Street ticker symbol "MSWV" on the OTCQX, and will operate under the "Main Street Financial Services Corp." name, and the combined bank will operate under the "Main Street Bank Corp." name. The administrative and bank headquarters of the combined company will be in Wooster, Ohio. The combined company's Board of Directors will have thirteen directors, consisting of seven directors from Wayne and six directors from Main Street. Mark R. Witmer, Wayne's current Executive Chairman, will serve as Executive Chairman of the combined company Board of Directors. Nicholas A. Sparachane, Main Street's current Chairman, will serve as Vice Chairman of the combined company Board of Directors. The combined company will be led by an experienced management team that is comprised of individuals with significant financial services industry experience, including Executive Chairman Witmer and: James R. VanSickle II, Wayne's current President and Chief Executive Officer, will serve as President and Chief Executive Officer of the combined company and Chief Executive Officer of the combined subsidiary bank. Mr. VanSickle will also serve as the interim Chief Financial Officer of the combined company and subsidiary bank. Richard A. Lucas, Main Street's current Chief Executive Officer, will serve as President of the combined bank subsidiary. Todd J. Simko, Main Street's current Executive Vice President & Chief Business & Risk Officer, will serve as Executive Vice President and Chief Operating Officer of the combined bank subsidiary. Promptly after the date of this announcement, Main Street and Wayne will prepare a joint proxy statement to be presented to the shareholders of each of Main Street and Wayne, seeking approval of the transaction. If an exemption from registration under the Securities Act of 1933 is not reasonably and satisfactorily available for the issuance of the shares of Main Street common stock, Main Street and Wayne will cooperate in the preparation and filing with the SEC a Form S-4 registration statement for the Main Street shares. The transaction is expected to close in the second half of 2023, subject to satisfaction of customary closing conditions, including regulatory approvals and approvals from both of Wayne and Main Street shareholders. Directors and certain executive officers of both companies have entered into voting support agreements to vote their shares in favor of the proposed transaction.

08:17 EST Horizon updates Uplizna data from analyses of the N-MOmentum trial for NMOSD - Horizon Therapeutics announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica spectrum disorder will be presented at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum, February 23-25, 2023, in San Diego. These data suggest UPLIZNA does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. UPLIZNA is the first and only B-cell-depleting monotherapy approved by the U.S. Food and Drug Administration and the European Commission for the treatment of NMOSD in adults who are anti-aquaporin-4 immunoglobulin G seropositive . "UPLIZNA prevents NMOSD attacks by targeting CD19-expressing B cells that are a key driver of NMOSD activity," said Bruce Cree, M.D., Ph.D., MAS, study author and professor of Clinical Neurology at the University of California San Francisco Weill Institute for Neurosciences. "Through ongoing studies and clinical use, we are learning that UPLIZNA's impact on NMOSD activity is very focused and may not interfere with certain other immune responses. Patients treated with UPLIZNA appear to not be more susceptibile to COVID-19 infections or to develop waning immunity from prior vaccinations due to treatment."

08:16 EST Enlivex receives clearance from Spanish AEMPS for Phase I/II of Allocetra - Enlivex Therapeutics announced that the Spanish Agency of Medicines and Medical Devices, AEMPS, has authorized the expansion of the Company's Phase I/II of Allocetra in patients with advanced solid malignancies. The clearance of the Phase I/II by the AEMPS follows recent announcements by the Company that the study received IND clearance from the U.S. Food And Drug Administration for recruitment of patients in the U.S., the independent Data Safety Monitoring Board has completed its prespecified data review for the first cohort of patients in the Phase I/II trial and the Israeli Ministry of Health had reviewed the data and provided regulatory clearance to continue the study and open the subsequent high dose monotherapy and combination cohorts. The Phase I/II multi-center clinical trial has been designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors. The Phase I/II trial was initiated following encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra was combined with a PD1 checkpoint inhibitor in a murine model of ovarian cancer, and additional models that demonstrated statistically significant survival benefit when Allocetra was combined with a PD1 or CTLA-4 checkpoint inhibitors in a murine model of peritoneal mesothelioma. Einat Galamidi, MD., Vice President, Medical of Enlivex, stated "We are pleased with the AEMPS' regulatory clearance to expand our clinical trial into Spain. We believe that AllocetraTM has the potential to provide a paradigm shift in treatment of advanced solid tumors, and we look forward to data readouts, including safety and potential indication of effect in patients, currently expected during 2023 and 2024."

08:13 EST uniQure announces HOPE-B trial published in NEJM - uniQure N.V. announced that its partner, CSL, announced the publication in the New England Journal of Medicine, NEJM, of results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX. HEMGENIX is the first and only gene therapy approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes. The multi-year clinical development of HEMGENIX was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialize the treatment. HEMGENIX was approved in November 2022 by the U.S. Food and Drug Administration, and in February 2023 by the European Commission for the European Union. Results from the HOPE-B trial, the largest gene therapy study in hemophilia B to date, were considered by the authors to demonstrate that HEMGENIX is superior to routine factor IX prophylaxis in Annualized Bleeding Rate, factor IX activity, factor IX therapy consumption, factor IX infusion rate, and spontaneous and joint bleeding ABR. Increased factor IX activity was also apparent from week 3 and maintained over 18 months. There were no reported serious adverse events related to treatment with HEMGENIX. The most common adverse reactions were elevated ALT, headache, blood creatine kinase elevations, flu-like symptoms, infusion-related reactions, fatigue, malaise and elevated AST.

08:10 EST Zhongchao renews partnership with Johnson & Johnson China - Zhongchao (ZCMD) has renewed the partnership between Zhongchao Medical Shanghai, of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, and Johnson & Johnson (JNJ) China. The renewed partnership is expected to further strengthen two parities' cooperation in the global advanced field of innovative medical and health. J&J is committed to providing innovative comprehensive medical solutions for Chinese patients and medical and health professionals. Pursuant to the cooperation agreement, Zhongchao Shanghai will provide digital education, multimedia courseware production, medical editing, and related design services for J&J in mainland China.

08:09 EST Cheniere Energy Partners initiates pre-filing review process with FERC - Cheniere Energy Partners (CQP), a subsidiary of Cheniere Energy (LNG), announced that certain of its subsidiaries have initiated the pre-filing review process under the National Environmental Policy Act with the Federal Energy Regulatory Commission, or FERC, for the proposed Sabine Pass Stage 5 Expansion Project adjacent to the existing Sabine Pass Liquefaction Project. The SPL Expansion Project is being designed for total production capacity of approximately 20 million tons per annum of liquefied natural gas. The SPL Expansion Project is being designed to include up to three large-scale liquefaction trains, each with a production capacity of approximately 6.5 mtpa of LNG, a boil-off-gas re-liquefaction unit with an approximate production capacity of 0.75 mtpa of LNG, and two 220,000m3 LNG storage tanks. The SPL Expansion Project is being designed with accommodations for waste heat recovery as well as carbon capture from acid gas removal units. The SPL Expansion Project is expected to benefit from the significant existing infrastructure at the SPL Project and contemplates various enhancements to its current capabilities, including optimized ship loading at the existing marine facilities. Feed gas related to the SPL Expansion Project is expected to be transported via a combination of new and existing pipelines currently supplying the SPL Project. Cheniere Partners has engaged Bechtel Energy, Inc. to complete a Front-End Engineering and Design study of the SPL Expansion Project.

08:04 EST Rent-A-Center to be known as Upbound Group - Rent-A-Center announced it will now be known as Upbound Group, an omni-channel platform company that enables a broader range of consumers to access flexible financial solutions. The company will begin to trade under the ticker (UPBD) starting on February 27.

07:59 EST TriMas to acquire operating net assets of Weldmac, terms undisclosed - TriMas announced that it has signed an agreement to acquire the operating net assets of Weldmac, a designer and manufacturer of metal fabricated components and assemblies for the aerospace, defense and space launch end markets. Upon closing, which is anticipated to occur in the coming months, Weldmac will become part of our TriMas Aerospace group and further advance the strategic growth of our integrated structural solutions product lines comprised of RSA Engineered Products and Martinic Engineering. Located in El Cajon, California, Weldmac is a premier designer and manufacturer of highly-engineered components for a broad range of critical applications across the aerospace, defense, commercial power and space launch industries. Offering numerous AS9100D and National Aerospace and Defense Contractors Accreditation Program certified manufacturing services, Weldmac's comprehensive processes include welding, stamping, punching, hydroforming, forging, laser cutting, custom tooling and machining, as well as advanced quality control inspections and complex assembly utilizing a variety of metals. Weldmac's manufacturing complex is equipped with a wide variety of state-of-the-art lasers, metal forming and fabrication equipment. Weldmac currently operates as a private, family estate-owned company, and generated approximately $33M in revenue in FY22.

07:56 EST Belden CEO Roel Vestjens resigns, Ashish Chand succeeds - Belden announced that Ashish Chand, EVP of Industrial Automation Solutions and Managing Director of APAC, has been appointed president and CEO. In connection with his appointment, Chand has been appointed to Belden's board of directors. The appointments are effective immediately. Chand succeeds Roel Vestjens, who has resigned from his position as president and CEO and as a member of Belden's board for personal reasons. The company said Vestjens' resignation is unrelated to Belden's strategy, operations, financial reporting, or any other matter related to the performance of the company.

07:50 EST Signal Gold announces diamond drill results from Goldboro Project - Signal Gold announced diamond drill results from a growth exploration program at its Goldboro Project in Nova Scotia. The growth exploration program, comprised of 2,870 metres in 15 drill holes of diamond drilling, has successfully discovered continued gold mineralization up to 325 metres to the west of the existing Goldboro Deposit Mineral Resource, and mineralization remains open along strike to the west and at depth. Critically, the results demonstrated the same style of gold mineralization and host environment as the Goldboro Deposit. Eight occurrences of visible gold were observed in 102 separate intersections of gold mineralization. Drilling also demonstrated that increased gold mineralization and alteration is coincident with the targeted Induced Polarization chargeability and Very Low Frequency trends. This geophysical signature, along with the current geological interpretation, suggests that the structure which hosts the Goldboro Deposit potentially extends two kilometres west of the current mineralization and is coincident with the past producing Dolliver Mountain Mine. Selected composited highlights from the drill program include: 20.59 g/t gold over 3.0 metres in hole BR-23-383 including 113.90 g/t gold over 0.5 metres; 9.46 g/t gold over 2.0 metres in hole BR-23-381 including 15.40 g/t gold over 0.5 metres; 7.29 g/t gold over 2.5 metres in hole BR-23-382; 4.84 g/t gold over 3.0 metres in hole BR-23-385; and 2.72 g/t gold over 3.5 metres in hole BR-23-385 including 13.40 g/t gold over 0.5 metres. Significant high-grades were also intersected, including: 130.70 g/t gold over 0.5 metres at 79.9 metres in hole BR-22-380; 47.20 g/t gold over 0.5 metres at 229.7 metres in hole BR-22-374; 77.70 g/t gold over 0.5 metres at 123.0 meters in hole BR-22-379; 21.00 g/t gold over 1.0 metres at 210.3 metres in hole BR-22-377; and 28.10 g/t gold over 0.5 metres at 112.1 metres in hole BR-23-381.

07:47 EST Agra Ventures appoints Kuzyk as permanent CEO, director - Agra Ventures (AGFAF) announces that its Board of Directors has appointed Nick Kuzyk as AGRA's CEO and Director on a permanent basis effective March 1, 2023, subject to the final acceptance of the Canadian Securities Exchange. Based on his performance as Interim CEO and Director over the past six months, the Board has deemed it appropriate for Kuzyk to continue in the roles and, therefore, the search for a permanent CEO is concluded. As previously announced, Nick has cannabis industry experience as the former Chief Strategy Officer and SVP Capital Markets of High Tide Inc. (HITI) from its inception in 2018 until the founding of his independent practice in 2020.

07:45 EST Papa John's falls almost 3% after Q4 report, North America SSS up 1% - Shares are down 2.77% or $2.56 per share to $89.78 in pre-market trading on Thursday.

07:43 EST Vermeer to integrate VPS Payload with Draganfly's Commander 3XL - Draganfly announces that Vermeer will integrate its VPS Payload with Draganfly's Commander 3XL. This partnership will enable Draganfly to collaborate with Vermeer's military and government clients and create solutions using the Company's innovative drone technology. Draganfly's Commander 3XL drone will be integrated with Vermeer's VPS as part of its modular unmanned aerial vehicle platform. VPS technology enables aerial platforms to determine their location in contested, spoofed, and GPS-denied environments. "Our team designed and manufactured the Commander 3XL drone to ensure it was compatible with various interchangeable payloads. Integrating Vermeer's VPS technology with the Commander 3XL will help improve military and defense intelligence, surveillance, and reconnaissance missions," said Cameron Chell, President, and CEO of Draganfly. "We are thrilled to partner with Vermeer to create solutions that help defense agencies protect life, mitigate risk, and reduce liability."

07:41 EST Lilium, Collins Aerospace partner to build Innovative Inceptor System - Lilium has teamed with Collins Aerospace, to design, develop and build the Lilium Jet's inceptors - the innovative sidestick system used by the pilot to control the aircraft. The Lilium Jet inceptors will provide safe and intuitive handling qualities, easy access to functionalities, and an aesthetic, ergonomic design. While integrating all conventional mechanical and electrical flight controls into two sidesticks, the Collins Aerospace system brings a new piloting philosophy for single pilot operations in the eVTOL realm. The system will also be designed to bring significant space and weight savings compared to conventional sidesticks. Lilium's collaboration with Collins Aerospace continues Lilium's strategy of teaming up with established tier one aerospace suppliers to support certification and prepare the industrial ramp-up. As part of the supplier agreement, Collins Aerospace, with its extensive experience in developing and certifying inceptors for commercial jets, will certify the Lilium Jet's inceptors to commercial aviation standards.

07:38 EST Aldeyra advances ADX-246, ADX-248 to clinical testing - Aldeyra announced the advancement of two investigational new drug candidates, ADX-246 and ADX-248, to clinical testing, pending completion of FDA investigational new drug, or IND, requirements. ADX-246 and ADX-248 represent the most recent group of product candidates generated from Aldeyra's systems-based drug discovery and development engine focused on novel RASP modulators designed to decrease immune responses that lead to disease. Pending completion of the IND requirements, a Phase 1 clinical trial of orally administered ADX-246 for the treatment of systemic immune-mediated diseases, and a Phase 1/2 clinical trial of intravitreally injected ADX-248 for the treatment of geographic atrophy, a sight-threatening retinal disease, are expected to initiate in the second half of 2023 or early 2024.

07:34 EST Domino's Pizza sees FY23 CapEx $90M-$100M

07:34 EST Domino's Pizza cuts two-to three-year outlook for global retail sales growth - Given the current macro-economic headwinds that are impacting the company's U.S. delivery business in particular, the company is updating its two-to three-year outlook from 6% to 10% global retail sales growth, excluding foreign currency impact to 4% to 8% global retail sales growth, excluding foreign currency impact and global net unit growth from 6% to 8% to 5% to 7%. The company expects results for fiscal 2023 to come in towards the low-end of the ranges for both metrics. The company looks forward to providing more details at an Investor Day that will be held before the end of calendar 2023.

07:32 EST Ruth's Hospitality sees FY23 capital expenditures $45M-$50M - Sees FY23 tax rate 17%-19%.

07:28 EST Gamesquare Esports appoint Tyler 'Ninja' Blevins as CIO - GameSquare announced gaming and pop culture phenomenon Tyler "Ninja" Blevins as its Chief Innovation Officer. As CIO, Blevins will tap his rich experience as an innovator in content to lead the company's efforts in pursuing emerging growth opportunities. This includes launching Ninja Labs, a GameSquare incubator to ideate and develop first-of-its-kind concepts and products directly focused on connecting with youth culture. Core to Blevins' mandate as CIO is to helm Ninja Labs, GameSquare's new innovation hub. Ninja Labs will serve as an innovation pipeline for the research and development of consumer products, original IP, and more. GameSquare partners will also be able to leverage Ninja Labs for future collaborations to connect with young consumers.

07:26 EST Assertio Holdings announces exchange offer of $30M of senior notes - Assertio entered into separate, privately negotiated exchange agreements with a limited number of holders of Assertio's currently outstanding 6.50% Convertible Senior Notes due 2027. Pursuant to the Exchange Agreements, Assertio will exchange $30.0 million aggregate principal amount of Exchanged Notes for a combination of a cash payment and an agreed number of shares of Assertio's common stock. Assertio will pay an aggregate of $10.5 million in cash and issue an aggregate of approximately 7.0 million shares of its common stock in the transactions. Assertio will not receive any cash proceeds from the issuance of the shares of its common stock. The transactions are subject to customary closing conditions and are expected to close on February 27, 2023. The shares of Assertio's common stock will be issued in private placements exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended. Upon completion of the transactions, Assertio expects to have $40.0 million aggregate principal remaining outstanding on its 6.50% Convertible Senior Notes due 2027.

07:24 EST Osino provides update on H1 2023 exploration program at Twin Hills Gold project - Osino Resources provides an update on its H1 2023 exploration budget for its wholly owned Twin Hills Gold Project in Namibia. David Underwood, Osino's VP Exploration commented: "With this round of drilling Osino aims to further grow the Twin Hills mineral resource by chasing previously identified mineralised shoots and stepping out along strike and at depth. We also aim to increase the reserve by converting inferred ounces to indicated, which will allow them to be included in the DFS and produce a more even gold production profile. In addition, we are now refocusing on near-pit exploration by testing some of our excellent targets and surface anomalies. We are particularly excited about the district targets at OJW and Rheinsheim which have large surface geochemical expressions, good rock chip and channel results on surface, and have never been drill-tested before."

07:23 EST Dollar General falls 7% to $210.00 after lowering Q4, FY22 outlook

07:22 EST Apollo Silver announces preliminary results from metallurgical testing - Apollo Silver reports preliminary results for silver recovery via bottle roll testing from its 2022 Metallurgical Test Program for the Waterloo deposit. The 2022 Test Program, which is one component of the 2022 Calico Technical Program, is an initial investigation in the overall metallurgical program for the Calico Silver Project, located in San Bernardino County, California. Up to 61% silver recovery using conventional cyanide leaching for ball mill fine grind material. Recovery of up to 72% achieved using a fluoride-assisted leach. Up to 80% silver recovery from ultra-fine grinding of the material. High Pressure Grinding Roll product showed a 50 to 100% percent increased silver recovery over conventional crushed material. Silver recoveries are favorable and in line with those of an active operation for a similar style deposit. These results will be incorporated into the ongoing work to update the Waterloo Property 2022 Mineral Resource Estimate 1, which forms part of the Calico Project MRE1. The resource update is expected to be completed as scheduled in early March. "These initial metallurgical test program results from the Waterloo property are positive," commented Apollo's President and CEO Tom Peregoodoff. "The results show that mineralization at Waterloo responds well to typical processing and recovery technologies, and they are consistent with recoveries at a currently operating silver mine. These results are being incorporated into the ongoing resource estimation work program which we anticipate will be complete in early March. Final results and reporting for the remaining test work for the program are pending, however we expect these to be available in March."

07:22 EST Kimbell Royalty Partners sees 2023 net production 16.3-18.1 Mboe/d

07:20 EST SpringBig introduces two marketing features, debuts new brand identity - springbig debuted its new logo and added two marketing features to its suite of marketing solutions. "The Company's new logo highlights springbig's growth and reaffirms its commitment to helping businesses cultivate rewarding connections with their customers; while the Company's new brand identity, the springbig Bolt, exemplifies the brand's evolution as a leader in SaaS-based marketing solutions," the company said. springbig has also added two marketing features to its renowned suite of solutions: Build Your Own Audience and Compare Campaigns. "Our latest features elevate the marketing efforts of dispensary owners and eliminate the need for additional customer data platforms," said Jeffrey Harris, CEO of springbig. "These additions to the springbig platform will help our clients create tailor-made marketing campaigns and offers that make customers feel seen and appreciated."

07:18 EST Emerita Resources announces additional assay results from La Romanera Deposit - Emerita Resources announces additional assay results from the ongoing 2022 - 2023 delineation drilling program at La Romanera Deposit, part of Emerita's wholly owned Iberian Belt West project, IBW project. According to Joaquin Merino-Marquez, P.Geo., Emerita's President and Director, "These results in the deep central zone of the deposit increase the resource potential of La Romanera at depth. The company will drill step outs around holes LR087 and LR107, at a 50 m by 50 m spacing for resource estimation. The company maintains 14 rigs on the IBW project. Downhole Electromagnetics and mise a la masse will be performed on LR087 and two other existing drillholes to map the extensions of mineralization at depth beyond the current 500 m depth. This technique has been applied on deeper targets at other locations in the Iberian Pyrite Belt with considerable success."

07:18 EST Skylight Health announces closure of operations in Colorado - Skylight Health announced the closure of Rocky Mountain Health Care clinics in Colorado as part of its continued effort to streamline its business and aggressively cut costs to preserve cash. "We have come to realize that we need to shed all of our loss-making businesses immediately to preserve the strong core business operating out of Florida," said Prad Sekar, CEO and Co-Founder of Skylight Health Group. "In order to survive during the difficult capital market environment, we have put an emphasis on generating positive cash flow and working to reduce liabilities. This will be a difficult process, but our team is determined to do what it takes to ensure we remain solvent with a view to focus our energy on our strong core value-based care business."

07:17 EST Atea Pharmaceuticals presents drug interaction profile of bemnifosbuvir - Atea Pharmaceuticals announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment is needed for CYP3A substrates or for drugs that are sensitive substrates of efflux and hepatic uptake transporters when co-administrated with bemnifosbuvir. CYP3A is an enzyme that metabolizes many classes of prescribed medicines and medicinal supplements, and efflux/hepatic uptake transporters regulate cellular trafficking of many drugs that are commonly prescribed to patients that are at high risk for severe COVID-19. These results were presented at the Conference on Retroviruses and Opportunistic Infections, which took place February 19-22, 2023 in Seattle, Washington. Bemnifosbuvir is an investigational orally administered, direct-acting antiviral. It is being evaluated in the global SUNRISE-3 Phase 3 registrational trial for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression to hospitalization and death. Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with Bemnifosbuvir: Results from a Phase 1, open-label, drug-drug interaction study suggest that no dose adjustments are needed when bemnifosbuvir is co-administered with drugs that are substrates of CYP3A4. In the study, bemnifosbuvir was administered with midazolam in 24 healthy participants and was well tolerated. Results showed a single dose of bemnifosbuvir only slightly increased the plasma exposure of MDZ. After repeat dosing of bemnifosbuvir simultaneously administered with MDZ, bemnifosbuvir increased plasma MDZ without affecting the exposure of the 1-hydroxymidazolam. Title: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP and OATP1B1 Mediated Transport Results from two Phase 1, open-label, drug-drug interaction studies suggest bemnifosbuvir has low potential to exhibit clinically meaningful inhibition of P-glycoprotein or breast cancer resistance protein/organic anion transporter polypeptide 1B1 drug transporters. Therefore, no dose adjustment is expected for drugs that are sensitive substrates of these transporters when co-administered with bemnifosbuvir. The efflux transporters P-gp and BCRP and the hepatic uptake transporter OATP1B1 regulate cellular trafficking of many drugs that are commonly prescribed to patients that are at high risk for severe COVID-19. These drugs include immunosuppressants, certain antibiotics, statins and other cardiovascular medications, certain diabetes medicines and chemotherapy. The studies assessed the effect of bemnifosbuvir on digoxin and rosuvastatin, which were used as P-gp and BCRP/OATP1B1 index drugs, respectively. Bemnifosbuvir administered with DIG or ROSU was well tolerated in the 29 healthy participants that were included in each study. A single high dose of bemnifosbuvir 1100 mg simultaneously administered with DIG slightly increased the Cmax of DIG yet had no effect on its AUC, which is consistent with the transient nature of bemnifosbuvir plasma pharmacokinetics. When dosed staggered, bemnifosbuvir did not affect the PK of DIG. A single dose of bemnifosbuvir 1100 mg administered with ROSU slightly increased the plasma exposure of ROSU.

07:15 EST Regeneron announces U.S. FDA accepted priority review for BLA for aflibercept - Regeneron Pharmaceuticals (REGN) announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the Biologics License Application, BLA, for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration, wAMD, diabetic macular edema, DME, and diabetic retinopathy. The FDA target action date is June 27, 2023 following the use of a priority review voucher. The BLA is supported by positive data from two pivotal trials - PULSAR in wAMD and PHOTON in DME - that were previously presented at the 55th Annual Scientific Session of The Retina Society in November 2022. In both trials, patients treated with aflibercept 8 mg met the primary endpoint of non-inferiority in vision gains for both the 12- and 16-week dosing regimens after initial monthly doses at 48 weeks compared to patients treated with an EYLEA Injection 8-week dosing regimen. Additionally, the vast majority of patients randomized to aflibercept 8 mg in both trials were able to maintain the 12- and 16-week dosing regimens to which they were respectively initiated through 48 weeks. The safety profile for aflibercept 8 mg was similar to EYLEA in both trials, and consistent with the known safety profile of EYLEA from previous clinical trials. Comparing aflibercept 8 mg to EYLEA, ocular adverse events occurred in 31% versus 28% in PHOTON and 38% versus 39% in PULSAR, and there were no cases of retinal vasculitis, occlusive retinitis or endophthalmitis in either trial. Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG (BAYRY). In the U.S., Regeneron maintains exclusive rights to EYLEA and aflibercept 8 mg. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of EYLEA and future sales of aflibercept 8 mg following any regulatory approvals.

07:14 EST Arvinas expects cash to fund requirements into 2026 - Based on its current operating plan, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of December 31, 2022, is sufficient to fund planned operating expenses and capital expenditure requirements into 2026.

07:13 EST C4 Therapeutics announces upcoming milestones - CFT7455: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial of Arm B1, evaluating CFT7455 as a monotherapy in MM, in the second half of 2023. CFT8634: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial in the second half of 2023 in synovial sarcoma and SMARCB1-null solid tumors. CFT1946: Continue site activation and patient enrollment of the dose escalation portion of the CFT1946 Phase 1/2 clinical trial in BRAF V600 mutant solid tumors. Present new preclinical data on the discovery and characterization of CFT1946 at 2023 AACR Annual Meeting in April. CFT8919: Submit an Investigational New Drug application for CFT8919 for the treatment of NSCLC in the first half of 2023.

07:09 EST Option Care Health board authorizes $250M share repurchase plan - The Company announced that its Board of Directors authorized the Company to repurchase up to $250 million shares of its common stock. The extent to which the Company repurchases shares, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company's management.

07:07 EST Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery - Sees "additional sales from key markets".

07:06 EST Moderna sees FY23 CapEx at about $1.0B and R&D expense at about $4.5B

07:05 EST Kymera Therapeutics announces 2023 objectives - The Company's recent data, generated in healthy volunteers and patients with HS, AD, hematological malignancies and solid tumors, demonstrated its industry leading, proprietary know-how in TPD and its progress in developing medicines in areas of significant patient and commercial opportunity. In January, the Company outlined its strategic objectives for 2023: Collaborate with Sanofi to initiate KT-474 Phase 2 clinical trial; Publish results of KT-474 Phase 1 trial including patient cohorts; Demonstrate clinical anti-tumor activity in target patient populations for KT-333 and KT-413; Initiate KT-253 Phase 1 trial in solid and hematological tumors and demonstrate clinical proof-of-mechanism in patients; Deliver at least 2 new development candidates ; Investigational New Drugs from the preclinical pipeline in areas of large clinical and commercial opportunity and pathways where TPD has potential to provide either the only or the best-in-class solution; Further expand the capabilities of Kymera's Pegasus platform and continue to leverage Kymera's E3 Ligase Whole-Body Atlas of over 600 unique E3 ligases, with a focus on tissue restricted E3 ligases; Expand novel molecular glue franchise in areas of unmet medical need, exploiting a newly identified degron motif; Advance existing collaborations, or execute additional strategic partnerships, that support the company's evolution into a fully integrated, global biopharmaceutical company

06:56 EST Snapchat rolls out new Sounds features - In a blog post, Snapchat said, "Today we're excited to announce Sounds Recommendations for Lenses and Sounds Sync for Camera Roll, new Sounds creative tools that make it even easier to create and share. With over 250 million Snapchatters engaging with augmented reality everyday, Snap's leading AR Lens technology combined with Sounds deliver both a hyper-expressive experience to engage with friends and a powerful distribution tool for artists to share their music with fans. Since launching Sounds, videos created with music from Sounds on Snapchat have collectively resulted in over 2.7 billion videos created and over 183 billion views! Sounds Recommendations for Lenses is a new way for Snapchatters to find relevant Sounds to complement a Lens. When applying a Lens to a photo or video, Snapchatters can tap the Sounds icon to access a list of relevant Sounds to add to a Snap. Available in the US and rolling out globally on iOS and Android. Sounds Sync for Camera Roll photos and video allows Snapchatters to create montage videos that are automatically in rhythm to the beat of audio tracks from the Sounds library. Snapchatters can select between 4-20 photos/videos from their camera roll. Available in the US and rolling out globally on iOS and coming to Android in March." Reference Link

06:55 EST Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940 - Moderna (MRNA) and Merck (MRK) announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the adjuvant treatment of patients with high-risk melanoma following complete resection. The FDA granted Breakthrough Therapy Designation based on positive data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. "The FDA's Breakthrough Designation for mRNA-4157/V940 in combination with KEYTRUDA reflects the excitement that we have for the potential promise of individualized cancer treatments. mRNA-4157/V940 in combination with KEYTRUDA provided the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial and potentially represents a new frontier in treating melanoma and other cancers. We look forward to publishing the full data set and sharing the results at an upcoming oncology medical conference, as well as continuing discussions with health authorities. We are grateful to the FDA for this designation," said Stephen Hoge, M.D., Moderna's President. "This is an important milestone in the development of mRNA-4157/V940 in combination with KEYTRUDA. We look forward to working with the FDA, in collaboration with Moderna, to conduct a rigorous and rapid clinical development program with a focus on addressing the needs of this important patient population," said Dr. Eric H. Rubin, senior vice president, global clinical development, Merck Research Laboratories.

06:48 EST Denbury sees 2023 CapEx $350M-$370M - Denbury announced 2023 capital budget range for oil and natural gas development of $350M-$370M, and for carbon capture, utilization, and storage, or CCUS, capital expenditures of $140M-$160M. 2023 capital expenditures will be focused on expanding the company's CO2 transportation and dedicated storage network by adding strategically-located sequestration sites to its portfolio, expanding existing sequestration sites with nearby leasing, and drilling a number of stratigraphic test wells. In addition, Denbury expects to acquire additional rights of way and long-lead items for CO2 pipeline connections to sequestration sites and industrial customers. Excluded from the capital budget amount are equity investments that Denbury may make from time to time to increase the scale of its CCUS operations.

06:46 EST Denbury sees 2023 oil and natural gas production 46K-49K BOE/day - Denbury anticipates oil and natural gas sales volumes for 2023 between 46,000 and 49,000 barrels of oil equivalent per day, with 97% of the volumes expected to be oil. The midpoint of the 2023 production range is up approximately 1.5% from 2022, primarily due to the anticipated commencement of production from the CCA EOR development in the second half of 2023. Lease operating expense is estimated to range between $29 and $31 per BOE during 2023, slightly higher than in 2022 primarily due to higher expected CO2 costs.

06:38 EST Alibaba CEO sees 'continued recovery in consumer sentiment' - We delivered a solid quarter despite softer demand, supply chain and logistics disruptions due to impact of changes in COVID-19 measures," said Daniel Zhang, Chairman and CEO of Alibaba Group. "Looking ahead, we expect continued recovery in consumer sentiment and economic activity. We are focused on driving growth for our customers amid the competitive landscape, and creating sustainable, long-term value for our shareholders." "During the past quarter, we continued to improve operating efficiency and cost optimization that resulted in robust profit growth," said Toby Xu, CFO of Alibaba Group. "Our net cash position remains strong and we continue to generate healthy cash flow. During the quarter ended December 31, 2022, we repurchased 45.4 million ADSs for approximately $3.3 billion under our share repurchase program as part of our ongoing commitment to improve our shareholder return."

06:29 EST Mercedes-Benz E-Class to feature TikTok, Angry Birds, Webex, Zoom - The company said, "Customers can look forward to a particularly immersive entertainment experience in the new E-Class. Music, games and streaming content can be experienced in the car with almost all the senses. Thanks to digital innovations in the interior, the E-Class is now more intelligent, achieving a new dimension of personalisation and interaction. At the same time, the electronic architecture is more software-driven and less hardware-driven. This forms the basis for more individual updating of the interior systems in the future. The computing functions of previously separate domains take place in a single processor. Screens and the MBUX infotainment system thus share a new, very powerful central onboard computer. This form of networking improves performance, as the data streams can be transmitted significantly faster. The E-Class launch starts with the Saloon model. The first models of the 214 series will arrive at the European dealerships in summer 2023. In the USA, the market launch will take place in autumn 2023...The entertainment experience for the front passenger is always impressive. On his/her optional screen, the front passenger can watch dynamic content such as TV or video streaming1 even when the driver at the wheel is looking over at them. This is because the display is switchable. The advanced camera-based visual shield function reduces its brightness and thus reduces the risk of distraction for the driver.The entertainment programme in the E-Class is more interactive than ever. The software experts at Mercedes-Benz have developed a new compatibility layer that allows the installation of third-party apps. The following apps are available on the central display on the launch of the E-Class: the entertainment platform "TikTok", the game "Angry Birds", the collaboration application "Webex", the office application "Zoom" and the browser "Vivaldi". In addition, the ZYNC entertainment portal offers video streaming, on-demand content, interactive experiences, local video programmes, sports, news, games and much more on the central and passenger displays, via one user interface. Another new feature is a selfie and video camera on top of the dashboard When the vehicle is stationary, the driver can participate in online video conferences via e.g. Webex, and take personal photos and videos." Reference Link

06:17 EST Bath & Body Works taking enterprise-wide effort to reduce expenses - The company announced today it is undertaking an enterprise-wide effort to reduce expenses and improve operating efficiency in the business. The company recently engaged external advisors to assist in a comprehensive analysis of margin expansion and expense reduction opportunities with the goal of positioning the business for improved profitability. The company is targeting $200M of annual cost savings with over half of those savings contemplated in its 2023 outlook, primarily impacting the second half of the year. A substantial portion of the remaining savings is expected to be realized in 2024.

06:05 EST Rolls-Royce sees 2023 operating profit GBP 0.8B-GBP 1B - Sees FCF GBP 0.6B-GBP 0.8B.

05:40 EST Jounce, Redx Pharma announce recommended all share merger transaction - Redx Pharma and Jounce Therapeutics announce an unanimously recommended business combination of the two companies via a proposed all share merger transaction. Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis. The business combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points in the near and medium term. The combined group's highest priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis, or IPF, with topline data expected in Q1 2024. ROCK2 inhibition is now a commercially validated target with potential in multiple disease areas, following the recent FDA approval and launch of the first drug with this mechanism of action. In addition to the ongoing clinical development plan in IPF, Redx has also generated supportive preclinical data that highlights the broad potential of next-generation ROCK2 inhibitors across a number of fibrotic indications where there remains a significant unmet need, which supports potential development opportunities in other interstitial lung diseases and cancer-associated fibrosis. Additionally, RXC004 is being developed as a targeted treatment for Wnt-ligand dependent cancers and is progressing through Phase 2 trials, and RXC008, a GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease, is expected to enter clinical development in H1 2024.At the time of the completion of the business combination, Jounce is expected to have around $155M of cash and cash equivalents, which net of any tail and closing costs results in at least $130M in cash and cash equivalents available to the combined group. Together with Redx's expected cash at completion would provide the combined group with cash runway into H2 2025. Based on Redx's fully diluted market capitalization of $294M as at the Last Practicable Date and Jounce's expected cash and cash equivalents at the time of completion, this implies a market value for the combined group of $425M, before taking into account the value of Jounce's existing clinical and non-clinical stage programs. Under the terms of the business combination, Redx Shareholders shall be entitled to receive 0.2105 Jounce Shares in exchange for each Redx Share. Jounce intends to conduct a reverse stock split of Jounce Shares in conjunction with the business combination, with a ratio of one new share for every five outstanding shares of Jounce. A reverse split is a share exchange transaction, without any impact on the amount of the share capital: only the number of outstanding shares is modified. If the reverse stock split is approved by Jounce Shareholders, the exchange ratio will be adjusted to 0.0421 Jounce Shares in exchange for each Redx Share. Immediately following completion of the business combination, including conversion of the Redx Convertible Loan Notes, Redx Shareholders are expected to own approximately 63% and Jounce shareholders approximately 37% of the share capital of the combined group. The business combination is expected to be implemented by way of a Scheme of Arrangement of Redx under Part 26 of the UK Companies Act, immediately preceded by a merger transaction between RM Special Holdings 3, an entity controlled by Redmile, and Jounce and its affiliates, which together will result in Jounce owning the entire issued and to be issued ordinary share capital of Redx. Further details of the Redmile Merger and the ability for eligible Redx Shareholders to request that their Redx Shares be transferred to Jounce via a similar merger structure are set out in the Rule 2.7 announcement. In connection with the business combination, a non-transferrable Contingent Value Right, or CVR, is expected to be distributed to Jounce Shareholders that held Jounce shares prior to completion of the business combination and holders of Jounce Share Awards immediately prior to completion of the business combination comprising vested options, relating to certain existing Jounce clinical and non-clinical stage programs. The CVRs shall entitle the relevant Jounce Shareholders to receive, on a pro rata basis, subject to certain terms and conditions, 80% of the net proceeds resulting from any sale, transfer, disposition, spin-off, or license of certain assets relating to such programs that is consummated within one year following the business combination, subject to one six-month extension term in certain limited circumstances, as set forth in the CVR agreement. The boards of both Redx and Jounce have unanimously recommended that shareholders vote in favor of the business combination. In connection with the business combination, Jounce has received irrevocable undertakings from Redx Shareholders who together own 76.6% of Redx's share capital as of 22 February 2023 and RM3 has entered into the Redmile merger agreement conditional on the Court sanctioning the Scheme and will receive the same exchange ratio. Both Redmile and Sofinnova have agreed to convert all the Redx Convertible Loan Notes held by them respectively as part of the transaction. Redx has also received voting and support agreements in respect of Jounce shares, representing, in aggregate, approximately 21.3% of the issued and outstanding share capital of Jounce. Full details of the undertakings and voting and support agreements are contained in the Rule 2.7 announcement. It is expected that the business combination will complete during the second quarter of 2023, subject to satisfaction or waiver of the conditions including approval of the Scheme by Redx Shareholders, Jounce Shareholder approvals, and customary regulatory approvals.

05:21 EST Leidos named principle contractor for London Luton Airport technology upgrades - Leidos was recently named the principle contractor for technology upgrades across multiple security checkpoints at London Luton Airport, or LLA. As one of the UK's busiest airports, LLA served over 13M passengers in 2022. As the principal contractor, Leidos manages all subcontractors and associated consultants working on the project. This includes oversight of building modifications to create two central image processing rooms. The company will also install its security systems and other third-party security solutions at the checkpoints. Under the agreement, Leidos will deploy 12 of its integrated ClearScan cabin baggage scanners and ProPassage automated tray return systems. ClearScan is a computed tomography scanner with advanced explosive detection algorithms. This capability eliminates the need to remove electronics and approved liquids from carry-on baggage. The large, automated ProPassage trays reduce the number of trays needed per passenger in the divest area and helps prevent sweep-outs, a common issue with light items in shallow trays. The combination of these two technologies will enable faster processing of passengers through the checkpoint.

05:08 EST AbbVie, Capsida announce expanded genetic medicines for eye diseases pact - AbbVie and Capsida Biotherapeutics announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus, or AAV, engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021. Under the terms of the expanded agreement, Capsida will receive $70M, consisting of upfront payments and a potential equity investment. For the three programs, Capsida may be eligible to receive up to $595M in option fees and research and development milestones, with potential for further commercial milestones. Capsida is also eligible to receive mid-to-high single-digit royalty payments on future product sales. Capsida will lead capsid discovery efforts for all programs using its high throughput AAV engineering platform and will be responsible for process development and early clinical manufacturing. AbbVie will lead innovative therapeutic cargo approaches and be responsible for development and commercialization.